Protea Biosciences 10-K 13 Feb 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 12, 2015	Jun. 30, 2014
Document Information [Line Items]
Entity Registrant Name	Protea Biosciences Group, Inc.
Entity Central Index Key	1335103
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	PRGB
Entity Common Stock, Shares Outstanding		66,588,600
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$33,901,853

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$322,877	$1,086,330
Trade accounts receivable, net	273,914	216,864
Other receivables	119,230	435,278
Inventory	161,301	465,334
Prepaid expenses	54,022	304,696
Total current assets	931,344	2,508,502
Property and equipment, net	2,960,090	2,886,176
Other noncurrent assets	136,693	23,249
Total Assets	4,028,127	5,417,927
Current Liabilities:
Current maturities on short and long-term debt	1,457,800	1,054,053
Accounts payable	1,253,385	759,021
Bank line of credit	3,000,000	2,725,000
Loans payable to stockholders, net of discount	1,381,498	465,883
Derivative liabilities	154,058	623,587
Obligation related to the letter of credit, net of discount	0	151,981
Other payables and accrued expenses	518,821	1,069,167
Total current liabilities	7,765,562	6,848,692
Long-term debt - net of current portion	1,817,237	1,580,260
Stockholders' Equity:
Preferred stock ($.0001 par value; 10,000,000 shares authorized; 3,337,725 and none issued or outstanding at December 31, 2014 and December 31, 2013)	334	0
Common stock ($.0001 par value; 200,000,000 shares authorized; 66,588,600 and 65,442,735 shares issued and outstanding at December 31, 2014 and December 31, 2013)	6,659	6,545
Additional paid in capital	64,305,743	55,351,613
Accumulated deficit	-69,867,118	-58,392,348
Accumulated other comprehensive (loss) income	-290	23,165
Total Stockholders' Equity (Deficit)	-5,554,672	-3,011,025
Total Liabilities and Stockholders' Equity	$4,028,127	$5,417,927

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	3,337,725	0
Preferred Stock, Shares Outstanding	3,337,725	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	66,588,600	65,442,735
Common stock, shares outstanding	66,588,600	65,442,735

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Total Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Gross revenue	$1,768,312	$1,223,492
Cost of revenue	-871,904	-932,780
Gross profit	896,408	290,712
Selling, general, administrative expenses	-8,736,478	-7,842,673
Research and development expense	-2,853,078	-2,772,926
Loss from operations	-10,693,148	-10,324,887
Other income (expense):
Interest and exchange income (expense)	27,072	13,129
Interest expense	-745,277	-746,159
Debt conversion cost	0	-724,623
Loss on asset disposal	-19,144	-15,116
Gain on subsidary sale	1,245,712	0
Change in fair value of derivative	-1,289,985	379,986
Total other income (expense)	-781,622	-1,092,783
Loss before income taxes	-11,474,770	-11,417,670
Income taxes	0	0
Net loss	-11,474,770	-11,417,670
Foreign currency translation adjustment	-23,455	29,568
Total comprehensive loss	($11,498,225)	($11,388,102)
Net loss per share - basic and diluted (in dollars per share)	($0.17)	($0.25)
Weighted average number of shares outstanding - basic and diluted (in shares)	67,762,628	45,044,638

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)		Total	Preferred Stock [Member]	Common Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2012		($7,903,831)		$3,188		$39,074,062	($46,974,678)	($6,403)
Balance (in shares) at Dec. 31, 2012				31,879,247
Issuance of stock for cash		8,755,705		2,116		8,753,589	0	0
Issuance of stock for cash (in shares)				21,164,846
Issuance of stock upon conversion of convertible debentures		5,644,948		1,130		5,643,818	0	0
Issuance of stock upon conversion of convertible debentures (in shares)				11,289,895
Issuance of stock for services		299,994		58		299,936	0	0
Issuance of stock for services (in shares)				581,247
Issuance of stock under anti-dilution provision		0		53		-53	0	0
Issuance of stock under anti-dilution provision (in shares)				527,500
Stock-based compensation expense		872,967		0		872,967	0	0
Stock warrants issued as part of convertible debentures		763,659		0		763,659	0	0
Stock warrants issued for related party debt and letter of credit		304,390		0		304,390	0	0
Stock warrants issued to placement agent		597,133		0		597,133	0	0
Recognition of derivative liabilities		-957,888		0		-957,888	0	0
Net loss		-11,417,670		0		0	-11,417,670	0
Foreign currency translation adjustment		29,568		0		0	0	29,568
Balance at Dec. 31, 2013		-3,011,025	0	6,545		55,351,613	-58,392,348	23,165
Balance (in shares) at Dec. 31, 2013			0	65,442,735
Issuance of stock for cash		3,713,872	227	0		3,713,645	0	0
Issuance of stock for cash (in shares)			2,264,238	0
Issuance of stock upon conversion of convertible debentures		2,146,975	107	0		2,146,868	0	0
Issuance of stock upon conversion of convertible debentures (in shares)			1,073,487	0
Issuance of stock for services		880,373	0	111		880,262	0	0
Issuance of stock for services (in shares)			0	1,112,348
Stock options exercised		19,265	0	2	[1]	19,263	0	0
Stock options exercised (in shares)			0	25,000	[1]
Stock warrants exercised		0	0	1	[2]	-1	0	0
Stock warrants exercised (in shares)			0	8,517	[2]
Stock-based compensation expense		283,481	0	0		283,481	0	0
Stock warrants issued as part of convertible debentures	[3],[4]		2,146,869
Stock warrants issued for services and debt		150,409	0	0		150,409	0	0
Stock warrants issued to placement agent		-1,861	0	0		-1,861	0	0
Recognition of derivative liabilities		-9,298	0	0		-9,298	0	0
Anti-dilution shares to be issued		1,771,362	0	0		1,771,362	0	0
Net loss		-11,474,770	0	0		0	-11,474,770
Foreign currency translation adjustment		-23,455	0	0		0	0	-23,455
Balance at Dec. 31, 2014		($5,554,672)	$334	$6,659		$64,305,743	($69,867,118)	($290)
Balance (in shares) at Dec. 31, 2014			3,337,725	66,588,600
[1]	Shares issued for exercised stock options and does not contain an anti-dilution provision
[2]	Shares issued under cashless stock warrant exercise and does not contain an anti-dilution provision
[3]	Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
[4]	Shares issued contain an anti-dilution provision expiring upon the conversion to common stock.

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Issuance Cost of Stock Issued for Cash			$1,826,718
Issuance Cost	105,168
Common Stock, Par or Stated Value Per Share	$0.00		$0.00
Preferred stock, par value (in dollars per share)	$0.00		$0.00
Preferred Stock [Member]
Issuance Cost of Stock Issued for Cash	$814,604
Preferred stock, par value (in dollars per share)	$0.00	[1]
[1]	Shares issued contain an anti-dilution provision expiring upon the conversion to common stock.

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($11,474,770)	($11,417,670)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	825,780	844,888
Non-cash compensation	283,481	872,967
Issuance of common stock and warrants for services	1,035,462	345,678
Issuance of preferred and common stock for accrued interest	70,976	372,232
Accretion of convertible debenture discount	192,421	137,552
Debt conversion costs associated with inducement	0	724,623
Loss on disposal of fixed assets	19,144	15,116
Gain on subsidiary sale	-1,245,712	0
Bad debt expense	3,000	4,000
Expense (income) from change in fair value of derivative	1,289,985	-379,986
Net change in assets: Decrease (increase)
Trade accounts receivable	-60,050	-93,143
Prepaid expenses	235,877	-275,129
Other receivables	-198,081	-127,038
Inventory	304,033	439,852
Net change in liabilities: Increase (decrease)
Trade accounts payable	810,598	-1,989,467
Other payables and accrued expenses	575,043	304,707
Net cash used in operating activities	-7,332,813	-10,220,818
Cash flows from investing activities:
Purchase of and deposits on equipment	-413,806	-478,899
Proceeds from sale of equipment	6,000	1,000
Proceeds from subsidiary sale	586,638	0
Cash divested from subsidary sale	-63,185
Net cash provided by/used in investing activities	115,647	-477,899
Cash flows from financing activities:
Net advances on bank line of credit	275,000	0
Proceeds from sale of preferred stock, net	3,713,872	0
Proceeds from sale of common stock, net	13,750	9,352,837
Proceeds from short and long-term debt	536,000	1,994,500
Proceeds from shareholder debt	3,595,000	1,000,000
Repayment of shareholder, short and long-term debt	-1,420,351	-858,157
Proceeds from Obligation related to the Letter of Credit	0	600,000
Repayment of Obligation related to the Letter of Credit	-238,695	-361,305
Financing costs	0	0
Net cash provided by financing activities	6,474,576	11,727,875
Effect of exchange rate changes on cash	-20,863	29,568
Net (decrease) increase in cash	-763,453	1,058,726
Cash, beginning of period	1,086,330	27,604
Cash, end of period	322,877	1,086,330
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	319,947	383,288
Supplemental disclosure of non-cash investing and financing activities:
Financed equipment	501,917	477,817
Debt converted to company stock	2,146,976	5,644,948
Common stock shares issuable	$1,771,362	$0

Description_of_Company_and_Nat

Description of Company and Nature of Business	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. Description of Company and Nature of Business
	Protea Biosciences Group, Inc. (referred to as “Protea”, “the Company”, “we”, “us” and “our”) is an emerging growth, molecular information company providing innovative bioanalytical technologies and capabilities to the pharmaceutical, diagnostic and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the products of all living cells and life forms.
	The Company is applying its technology to the development of next generation "direct molecular imaging" technology and service capabilities that support pharmaceutical and life science research, and enable more rapid and comprehensive molecular profiling of human disease.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Protea Biosciences Group, Inc. and its wholly-owned subsidiary, Protea Biosciences, Inc. All material accounts and transactions have been eliminated in consolidation. During 2014, the Company sold Proteabio Europe but retains continued involvement through an equity method investment in AzurRx BioPharma, Inc., the Buyer of Proteabio Europe. (See Note 3 Subsidiary Sale) As the sale was not fully consummated due to an outstanding contingency, the transaction was not recognized until December 12, 2014. As such, the results of Proteabio Europe are consolidated into the Company’s financial statements for the year ended December 31, 2014.
	Going Concern
	The Company’s financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has funded its activities to date almost exclusively from debt and equity financings. The Company will continue to require substantial funds to advance the research and development of its core technologies and to develop new products and services based upon its proprietary protein recovery and identification technologies.
	Management intends to meet its operating cash flow requirements primarily from the sale of equity and debt securities. The Company seeks additional capital through sales of equity securities or convertible debt and, if appropriate, to pursue partnerships to advance various research and development activities. The Company may also consider the sale of certain assets, or entering into a transaction such as a merger with a business complimentary to theirs.
	While the Company believes that it will be successful in obtaining the necessary financing to fund its operations, they have no committed sources of funding and are not assured that additional funding will be available to them. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.
	Estimates and Assumptions
	The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. The Company has cash on deposit at banks that may exceed the federally-insured limits at times.
	Trade Accounts Receivable
	Trade accounts receivable are reported at the amount management expects to collect from outstanding balances. Differences between the amount due and the amount management expects to collect are reported in the statement of operations of the year in which those differences are determined, with an offsetting entry to a valuation allowance for trade accounts receivable. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable. The Company performs ongoing credit evaluations of its customers and generally does not require collateral.
	The Company maintains allowances for doubtful accounts based on management’s analysis of historical losses from uncollectible accounts and risks identified for specific customers who may not be able to make required payments. If the financial condition of customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. An allowance of $3,000 was deemed necessary as of December 31, 2014 and $4,000 as of December 31, 2013.
	Equity Method Investments
	The Company’s 33% interest in AzurRx BioPharma, Inc. (“AzurRx”) is accounted for on the equity method. AzurRx is a private biotechnology company formed to focus on the development of the early stage pharmaceutical assets of ProteaBio Europe.  Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee Company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee Company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Consolidated Balance Sheets and Consolidated Statements of Income; however, the Company’s share of the earnings or losses of the Investee Company is reflected in the caption “Income from equity method investments” in the Consolidated Statements of Income. The Company’s carrying value in an equity method Investee company would be reflected in the caption “Equity method investments” in the Company’s Consolidated Balance Sheets.
	Other Receivables and Other Noncurrent assets
	Other receivables, which reflect amounts from non-trade activity and other noncurrent assets, consist of the following at:
			December 31, 2014			December 31, 2013
	French government R&D credit		$	-		$	400,379
	Other receivables			119,230			34,899
	Other receivables - current		$	119,230		$	435,278
	Deposits		$	136,693		$	23,249
	Other noncurrent assets		$	136,693		$	23,249
	Inventory
	Inventory represents finished goods and work in progress. Finished goods and work in progress consist primarily of specifically identifiable items that are valued at the lower of cost or fair market value using the first-in, first-out (FIFO) method. Inventory consists of the following at:
			December 31, 2014			December 31, 2013
	Finished goods		$	18,739		$	360,607
	Work in progress			142,562			104,727
	Total Inventory		$	161,301		$	465,334
	Property and Equipment
	Expenditures for maintenance and repairs are charged to expense and the costs of significant improvements that extend the life of underlying assets are capitalized.
	Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows:
	Laboratory Equipment	5 - 10 years
	Computers	5 years
	Leasehold improvements	Life of lease
	Software	3 years
	Property and equipment consists of the following at:
			December 31, 2014			December 31, 2013
	Lab equipment		$	7,313,979		$	6,620,662
	Computer equipment			540,814			563,976
	Office equipment			229,785			248,490
	Leasehold improvements			434,304			477,682
				8,518,882			7,910,810
	Accumulated depreciation			-5,558,792			-5,024,634
	Property and equipment, net		$	2,960,090		$	2,886,176
	Depreciation expense is charged to either research and development or selling, general and administrative  expenses and totals $825,780 in 2014 and $844,888 in 2013.
	The Company evaluates the potential impairment of property and equipment whenever events or changes in circumstances indicate that the carrying value of a group of assets may not be recoverable. An impairment loss would be recognized when the carrying amount of the asset group exceeds the estimated undiscounted future cash flows expected to be generated from the use of the asset group and its eventual disposition. The amount of impairment loss to be recorded is measured as the excess of the carrying value of the asset group over its fair value. Fair value is generally determined using a discounted cash flow analysis or market prices for similar assets.
	Revenue Recognition
	We follow the provisions of FASB ASC 605, “Revenue Recognition”. We recognize revenue of products when persuasive evidence of a sale arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred /title has passed, and collectability of the sales price is reasonably assured. The Company recognizes revenue from the sale of its ProteaPlot™ software when bundled with the LAESI platform, which facilitates operating the instrument and storage and display of datasets. The Company also recognizes revenue of standalone sales of ProteaPlot™, which generally consists of additional user licenses. Revenue is recognized once the title is passed to the customer.
	We account for shipping and handling fees and costs in accordance with the provisions of FASB ASC 605-45-45, “Revenue Recognition – Principal Agent Considerations”, which requires all amounts charged to customers for shipping and handling to be classified as revenues. Shipping and handling costs charged to customers are recorded in the period the related product sales revenue is recognized.
	Regarding short-term service contracts, the majority of these service contracts involve the processing of imaging and bioanalytical samples for pharmaceutical and academic/clinical research laboratories. These contracts generally provide for a fixed fee for each method developed or sample processed and revenue is recognized when the analysis is complete and a report is delivered.
	For longer-term contracts involving multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. We perform this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, we account for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) have standalone value to the customer, and the delivery or performance of the service(s) is probable and substantially in our control. Revenue on multiple revenue arrangements is recognized using a proportional method for each separately identified element. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or, if there is no predominant deliverable, upon delivery of the final element of the arrangement.
	Revenues from grants are based upon internal costs that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by the Company that is related to the grants. The Company has revenue from four major components: molecular information services, LAESI instrument platform, research products, and grants and other collaboration revenues. Revenue by component was as follows:
			Year Ended
			December 31, 2014			December 31, 2013
	Molecular Information Services		$	504,750		$	199,220
	LAESI Instrument Platform			743,250			651,584
	Research Products			400,141			372,688
	Grants and Other Collaborations			120,171			-
	Gross Revenue		$	1,768,312		$	1,223,492
	A small number of customers have accounted for a substantial portion of our revenues in 2014. Five customers represented 42% of gross revenues for the year ended December 31, 2014. The Company is not dependent on a limited number of customers for sale of its products and services.
	Other Payables and Accrued Expenses
	Other payables and accrued expenses, which reflect amounts due from non-trade activity, consist of the following at:
		December 31, 2014			December 31, 2013
Accrued expenses		$	31,104		$	653,047
Accrued interest			201,844			39,911
Accrued warranties			50,000			81,250
Accrued payroll and benefits			219,973			286,979
Unearned revenue			15,900			7,980
Other payables and accrued expenses		$	518,821		$	1,069,167
Warranty Costs
The Company provides for a one-year warranty with the sale of its LAESI instrument. Additionally, the Company sells extended warranties for an additional cost. To date, the Company has not sold any extended warranties. All other product warranties are 90 days from the date of delivery of the goods. As the Company does not currently have sufficient historical data on warranty claims, the Company's estimates of anticipated rates of warranty claims and costs are primarily based on comparable industry metrics. The Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its product. During the year ended December 31, 2014, the Company recorded accrued warranty expense of $50,000 compared to $81,250 accrued warranty expense for the year ended December 31, 2013.
Foreign Currency
Foreign currency adjustments resulting from international sales are reflected in accumulated other comprehensive income/loss.
Advertising
The Company follows the policy of charging the costs of advertising to expense as incurred.
Research and Development Credit
The Company follows the policy of charging the costs of research and development to expense as incurred. Research and Development expense disclosed on the Consolidated Statement of Operations is net of the French Government Research Credit, which was $379,737 in 2014 and $398,285 in 2013.
Net Loss per Share
Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Common share equivalents (which may consist of convertible preferred stock and dividends, options, warrants and convertible debt) are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 84,834,000 and 56,711,000 at December 31, 2014 and 2013, respectively.
Reclassification
Certain amounts have been reclassified in the presentation of the Consolidated Financial Statements for the year ended December 31, 2013 to be consistent with the presentation in the Consolidated Financial Statements for the year ended December 31, 2014.  This reclassification had no impact on previously reported net loss, cash flow from operations or changes in stockholder equity.
Income Taxes
Deferred income taxes are reported using the liability method. Deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Stock-Based Compensation
The Company follows the provisions of FASB ASC 718, “Stock-Based Compensation”. Stock-Based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period. Fair value of Company stock options is estimated using the Black-Scholes option-pricing model. The associated compensation expense is recognized on a straight-line basis over the requisite service period, net of estimated forfeitures.
Estimating the fair value for stock options for each grant requires judgment, including estimating stock-price volatility, expected term, expected dividends and risk-free interest rates. The expected volatility rates are estimated based on the volatility of similar entities whose share information is publicly available. The expected term represents the average time that options are expected to be outstanding and is estimated based on the average of the contractual term and the vesting period of the options as provided in SEC Staff Accounting Bulletin #110 as the “simplified” method. The risk-free interest rate for periods approximating the expected term of the options is based on the U.S. Treasury yield curve in effect at the time of grant. Expected dividends are zero as the Company has no plans to issue dividends on common stock.
Prior to becoming a public company, the Company used an index to calculate the expected volatility component of the fair value model. Subsequent to becoming a public company and due to a lack of trading history, the Company utilizes a peer group to estimate its expected volatility assumptions used in the Black-Scholes option-pricing model. The Company completed an analysis and identified four similar companies considering their industry, stage of life cycle, size, and financial leverage. (See Note 9, Stock Options and Stock-Compensation)
Derivative Liabilities
The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks; however, the Company has certain financial instruments that are embedded derivatives associated with capital raises and common stock purchase warrants. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 810-10-05-4 and 815-40.  This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date.  In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion or exercise, the derivative liability is marked to fair value at the conversion date and then the related fair value is reclassified to equity.
Fair value of financial assets and liabilities – Derivative Instruments
We measure the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
The three levels of inputs used to measure fair value:
Level 1 – quoted prices in active markets for identical assets or liabilities.
Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable.
Level 3 – inputs that are unobservable (for example, the probability of a capital raise in a “binomial” methodology for valuation of a derivative liability directly related to the issuance of common stock warrants).
The Company has entered into certain financial instruments and contracts such as, equity financing arrangements for the issuance of common stock, which include anti-dilution arrangements and detachable stock warrants that are i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are recorded as derivative liabilities at fair value at the issuance date. Subsequent changes in fair value are recorded through the statement of operations.
The Company’s derivative liabilities are related to common stock issuances, detachable common stock purchase warrants (“warrants”) issued in conjunction with debt and common stock, or warrants issued to the placement agents for financial instrument issuances. We estimate fair values of the warrants that do contain “Down Round Protections” utilizing valuation models and techniques that have been developed and are widely accepted that take into account the additional value inherent in “Down Round Protection.” These widely accepted techniques include “Modified Binomial”, “Monte Carlo Simulation” and the “Lattice Model.” The “core” assumptions and inputs to the “Binomial” model are the same as for “Black-Scholes”, such as trading volatility, remaining term to maturity, market price, strike price, and risk free rates; all Level 2 inputs.  Fair value measurements are classified according to the lowest level input or value-driver that is significant to the valuation. A measurement may therefore be classified within Level 3 even though there may be significant inputs that are readily observable. However, a key input to a “Binomial” model (in our case, the “Monte Carlo Simulation”, for which we engaged an independent valuation firm to perform) is the probability of a future capital raise.  By definition, this input assumption does not meet the requirements for Level 1 or Level 2 outlined above; therefore, the entire fair value calculation is deemed to be Level 3 under accounting requirements due to this single Level 3 assumption. This input to the Monte Carlo Simulation model was developed with significant input from management based on its knowledge of the business, current financial position and the strategic business plan with its best efforts.
As discussed above, financial liabilities are considered Level 3 when their fair values are determined using pricing models or similar techniques and at least one significant model assumption or input is unobservable.  For the Company, the Level 3 financial liability is the derivative liability related to the common stock and warrants that include “Down Round Protection” and they were valued using the “Monte Carlo Simulation” technique.  This technique, while the majority of inputs are Level 2, necessarily incorporates a Capital Raise Assumption which is unobservable and, therefore, a Level 3 input.
A range of key quantitative assumptions related to the common stock and warrants issued during 2014 and 2013 are as follows:
		December 31, 2014
		Expected	Risk Free				Volatility				Probability of a Capital
		Life (Years)	Rate								Raise
Derivative liabilities		5-Jan			1.38	%			77.86	%	100	%
		December 31, 2013
		Expected		Risk Free		Volatility				Probability of a Capital
		Life (Years)		Rate						Raise
Derivative liabilities		5-Jan		0.13-1.75	%			83.3-88.3	%			100	%
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company’s derivative liabilities are related to common stock issuances, detachable warrants issued in conjunction with debt and common stock, or warrants issued to the placement agents for financial instrument issuances. The derivative liabilities measured at fair value on a recurring basis are summarized below:
		Fair Value Measurements at December 31, 2014
		Carrying Value			Level 1			Level 2			Level 3
Derivative liabilities – common stock		$	88,871			-			-		$	88,871
Derivative liabilities – warrants			65,187			-			-			65,187
Total		$	154,058			-			-		$	154,058
		Fair Value Measurements at December 31, 2013
		Carrying Value			Level 1			Level 2			Level 3
Derivative liabilities – common stock		$	558,799			-			-		$	558,799
Derivative liabilities – warrants			64,788			-			-			64,788
Total		$	623,587			-			-		$	623,587
As a result of the 2014 Preferred Stock issuance, the Company has an obligation to issue 10,122,067 shares of Common Stock related to anti-dilution protection rights to various stockholders. As the Company had not issued these shares at December 31, 2014, the fair value of these shares, which was $1,771,362, was reduced from the derivative liability, and recorded as Common Stock to be issued in additional paid in capital as of December 31, 2014. The table below provides a summary of the changes in fair value of the derivative liabilities measured at fair value on a recurring basis:
		Year Ended December 31, 2014
		Derivative			Derivative			Total Fair Value
		liabilities -			liabilities -			Measurements
		Common Stock			Warrants			Using Level 3
								Inputs
Beginning balance		$	558,799		$	64,788		$	623,587
Issuance of warrants			-			2,550			2,550
Anti-dilution shares to be issued			-1,771,362			-			-1,771,362
Unrealized (gain) loss on derivative liabilities			1,301,434			-11,449			1,289,985
Recognition of derivative liabilities			-			9,298			9,298
Ending balance		$	88,871		$	65,187		$	154,058
		Year Ended December 31, 2013
		Derivative			Derivative			Total Fair Value
		liabilities -			liabilities -			Measurements
		Common Stock			Warrants			Using Level 3
								Inputs
Beginning balance		$	-		$	-		$	-
Issuance of warrants			-			45,685			45,685
Unrealized (gain) loss on derivative liabilities			-257,846			-122,140			-379,986
Recognition of derivative liabilities			816,645			141,243			957,888
Ending balance		$	558,799		$	64,788		$	623,587
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
In April 2014, the FASB issued a standard that updated the guidance on Presentation of Financial Statements, and Property, Plant and Equipment. The amendments in this standard change the criteria for reporting discontinued operations for all public and nonpublic entities. The amendments also require new disclosures about discontinued operations and disposals of components of an entity that does not qualify for discontinued operations reporting. This guidance will become effective for all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years, and therefore will become effective for us as of the beginning of our 2015 fiscal year. The Company is evaluating the impact that this standard will have on its consolidated financial statements.
In May 2014, the FASB issued a standard on revenue recognition that provides a single, comprehensive revenue recognition model for all contracts with customers.  The standard is principle-based and provides a five-step model to determine the measurement of revenue and timing of when it is recognized. The core principle is that a company will recognize revenue to reflect the transfer of goods or services to customers at an amount that the company expects to be entitled to in exchange for those goods or services. This standard is to be applied retrospectively and is effective for fiscal years beginning after December 15, 2016. The Company is evaluating the impact that this standard will have on its consolidated financial statements.
In June 2014, the FASB issued authoritative guidance which eliminates the concept of a development stage entity. The incremental reporting requirements for presenting the development stage operations and cash flows since inception will no longer apply to development stage entities. The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 are to be applied retrospectively and are effective for fiscal years beginning after December 15, 2014. The Company has elected to early adopt this standard effective December 31, 2014 and removed all references to since inception values presented in the consolidated financial statements.
In June 2014, the FASB issued authoritative guidance on stock compensation, which requires performance targets that affect vesting and can be achieved after the requisite service period, to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If achievement of the performance target becomes probable before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The amendments are effective for fiscal years beginning after December 15, 2015. The Company is evaluating the impact that this standard will have on its consolidated financial statements.
In August 2014, the FASB issued authoritative guidance on going concern disclosures and financial statement presentation, which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). This standard provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the financial statement footnotes. This standard is effective for annual reporting periods ending after December 15, 2016, and to annual and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements and related disclosures.
In November, 2014, the FASB issued ASU 2014-16, "Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force)." The ASU clarifies how current guidance should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of a host contract. The ASU is effective for fiscal years and interim periods beginning after December 15, 2015. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements.

Subsidiary_Sale

Subsidiary Sale	12 Months Ended
	Dec. 31, 2014
Contingent Subsidiary Sale [Abstract]
Contingent Subsidiary Sale [Text Block]	3. Subsidiary Sale
	On June 13, 2014, the Company closed on an agreement for the sale of 100% of the issued and outstanding capital stock of Proteabio Europe to AzurRx BioPharma, Inc. (the “Buyer”) pursuant to the terms of a Stock Purchase and Sale Agreement (the “SPA”), dated as of May 21, 2014. Under the terms of the SPA the Buyer is required to raise gross proceeds from an equity or equity-linked financing in excess of $2,000,000, or the stock purchased would revert back to the Company. Under the terms of the SPA, the Company received the following consideration:
		i.	an aggregate amount of $300,000 (the “Purchase Price”) including $200,000 in cash and $100,000 from the forgiveness of outstanding indebtedness of the Company owed to the Buyer;
	ii.		100 shares of Series A Preferred Stock of the Buyer (the “Preferred Stock”) that is convertible into 33% of the issued and outstanding common stock of the Buyer; and
		iii.	the right to receive certain other contingent consideration to be paid upon the satisfaction of certain events, including (a) a one-time milestone payment of $2,000,000 due within (10) days of receipt of the first approval by the FDA of a New Drug Application or Biologics License Application for a Business Product; (b) royalty payments equal to 2.5% of net sales of Business Product up to $100,000,000 and 1.5% of net sales of Business Product in excess of $100,000,000 and (c) ten percent (10%) of the Transaction Value received in connection with a sale or transfer of the pharmaceutical development business of Proteabio Europe.
	Effective upon the closing of the Sale, Thijs Spoor, a former director of the Company, was appointed to serve as a director and the Executive Chairman of the Buyer. While the Board did not establish a special committee to evaluate the fairness of this related party transaction or obtain a fairness opinion, the Board nevertheless believes that the terms of the transaction are no less favorable to the Company and its shareholders than such terms that would have been obtained from an unaffiliated third party.
	In addition, the Company received $300,000 on March 27, 2014 upon the signing of the Option Agreement with the Buyer. All contingencies of the Option Agreement were satisfied upon the signing of the SPA.
	In connection with the closing, the Company assigned (i) to Proteabio Europe all of its rights, assets, know-how and intellectual property rights in connection with program PR1101 and those granted under the Joint Research and Development Agreement with Laboratoires Mayoly Spindler SAS dated March 22, 2010 and (ii) to the Buyer all amounts, together with any right of reimbursement, due to the Company in connection with outstanding shareholder loans.
	For the year ended December 31, 2014, the Company realized a gain on subsidiary sale of $1,245,712. Gross proceeds were $586,638 and included cash proceeds of $500,000, forgiveness of debt of $100,000 less legal costs of $13,362. Additionally, AzurRx funded the operations of Proteabio Europe after June 13, 2014, which amounted to $761,258 as of December 31, 2014.
	By December 12, 2014, the Buyer raised gross proceeds from an equity or equity-linked financing in excess of $2 million. As a result, the Company has deconsolidated the results of Proteabio Europe as of December 12, 2014 from the financial statements. In addition, the Company has recorded an investment that is accounted for on the equity method of accounting and consists of a 33% interest in the Buyer. The Company determined the  fair market value of the investment as having no value as AzurRx is still in early stages of organizing and has not reached commercialization. The net value of this investment as presented on our consolidated balance sheet at December 31, 2014 was $0.

Bank_Line_of_Credit

Bank Line of Credit	12 Months Ended
	Dec. 31, 2014
Bank Line of Credit [Abstract]
Bank Line of Credit [Text Block]	4. Bank Line of Credit
	The Company has a line of credit that is authorized to $3,000,000 and payable on demand. The interest rate is variable and is .75% plus prime with a minimum rate of 5.87%. At December 31, 2014, the balance was $3,000,000 compared to $2,725,000 as of December 31, 2013. During both periods, the interest rate payable was 5.87% and all covenants had been met. Borrowings under the line are secured by the personal guarantee of three board members and the estate of a former board member.

Loans_Payable_to_Stockholders

Loans Payable to Stockholders	12 Months Ended
	Dec. 31, 2014
Loan Payable [Abstract]
Loans Payable to Stockholders [Text Block]	5. Loans Payable to Stockholders
	On August 6, 2013, the Company entered into the Note and Warrant Purchase Agreement (the “Summit Agreement”) with Summit Resources, Inc. (“Summit”), an affiliate of Steve Antoline, a director of the Company, pursuant to which Summit acquired (a) a promissory note (the “Summit Note”) bearing simple interest at a rate of 10% per annum, in an aggregate principal amount of $600,000 and (b) a five year warrant to purchase 1,000,000 shares of common stock at an exercise price of $1.10 per share. The fair value of these warrants was estimated to be $134,117, which was recorded as a discount to the promissory note, and will be accreted based on the repayment of the obligation. In accordance with the terms of the Summit Agreement, up to $150,000 of the gross proceeds received by the Company from the sale of each LAESI instrument shall be used to repay the principal amounts due under the Summit Note. The Company repaid $423,915 as of December 31, 2014. Accretion expense of $94,757 was recognized during the year ended December 31, 2014, while no accretion expense was recorded in 2013. The outstanding balance, net of discount, was $136,725 as of December 31, 2014. As of December 31, 2014, a total of $130,000 in accounts receivable has been pledged to Summit.
	During 2014, the Company received advances equal to an aggregate of $1,415,000 from Summit. In exchange for a portion of the advances received, the Company entered into Note and Warrant Purchase Agreements and issued (a) one-year promissory notes bearing simple interest at the rate of 10% per annum to Summit in an aggregate principal amount of $1,415,000 and (b) five-year warrants to purchase up to 1,415,000 shares of common stock at an exercise price of $0.80 per share. On June 3, 2014, the Board approved an increase in the total offering amount of the promissory notes issuable to $1,500,000 from $900,000. The fair value of these warrants was estimated to be $101,177, which was recorded as a discount to the promissory note, and will be accreted based on the repayment of the obligation. The Company repaid $250,000 as of December 31, 2014. Accretion expense of $10,950 was recognized during the year ended December 31, 2014. The outstanding balance, net of discount, was $1,074,773 as of December 31, 2014.
	During 2014, the Company received advances equal to an aggregate of $540,000 from various directors and current stockholders of the Company. The Company repaid $370,000 to these related parties. No terms of repayment have been specified on the remaining aforementioned advances as of the filing date.
	From March 13, 2014 through September 30, 2014, the Company received advances equal to an aggregate of $2,076,000 from various directors and current stockholders of the Company. On April 2, 2014, the Board approved an offering of up to $300,000 in convertible one year promissory notes. On June 3, 2014, the Board approved an increase in the total offering amount of convertible notes issuable to $2,000,000 (the “Related Party Offering”). On September 25, 2014, the Board approved a subsequent increase in the total offering amount of convertible notes issuable to $3,000,000. In exchange for each advance, the Company entered into a Note Purchase Agreement, and issued a convertible one-year promissory note bearing simple interest at a rate of 10% per annum to directors and stockholders. Each $100,000 of outstanding principal and accrued unpaid interest underlying the note is automatically convertible into securities of the Company issued in a subsequent financing pursuant to which the Company raises at least $2,000,000 in gross proceeds (“Subsequent Financing”) at a conversion price that shall be equal to the purchase price payable for the securities issued in any such Subsequent Financing. As of October 31 and November 25, 2014, the Company converted these notes into 1,073,487 shares of preferred stock and issued warrants to purchase common stock in an aggregate amount of 4,293,948 shares to these directors and stockholders.

Obligation_Related_to_the_Lett

Obligation Related to the Letter of Credit	12 Months Ended
	Dec. 31, 2014
Obligation Related to Letter of Credit [Abstract]
Obligation Related to Letter of Credit [Text Block]	6. Obligation Related to the Letter of Credit
	On March 6, 2013, the Company entered into a Warrant Purchase and Reimbursement Agreement (the “Reimbursement Agreement”) with Steve Antoline, a director of the Company, pursuant to which Mr. Antoline agreed to issue a letter of credit, dated February 25, 2013 (the "Letter of Credit") for the benefit of MPR Associates, Inc. ("MPR") for the purpose of guaranteeing an amount equal to $600,000 (the “Purchase Order Amount”) due by the Company to MPR in connection with the production of certain LAESI instruments in exchange for (a) the agreement by the Company to reimburse Mr. Antoline for any amounts paid by him on behalf of the Company pursuant to the Letter of Credit, up to the Purchase Order Amount and (b) a five-year warrant to purchase up to 1,100,000 shares of common stock, issued to an affiliate of Mr. Antoline. During the first quarter of 2013, MPR drew $600,000 against the Letter of Credit. The fair value of these warrants was estimated to be $138,763, which was recorded as a discount to the Reimbursement Agreement balance of $600,000, and has been accreted based on the repayment of the obligation. Accretion expense of $55,204 was recognized during the year ended December 31, 2014 while $83,559 was recognized during the year ended December 31, 2013. As of December 31, 2013, $238,695 was due in connection with the terms of the Reimbursement Agreement. On January 21, and April 4, 2014, the Company repaid $147,860 and $90,835, respectively to Mr. Antoline and the Letter of Credit was paid in full.

Longterm_Debt

Long-term Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	7. Long-term Debt
	1) Note Payable to the West Virginia Development Office (“WVDO”)
	In March 2007, the Company obtained an 8-year loan in the amount of $685,000 from the WVDO. The note bears interest at 3% providing for 96 monthly principal and interest payments of $8,035 through April 2015, at which time the note is due and payable. The note is secured by equipment costing $1,057,167. As of December 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the WVDO approved a deferral of principal and interest until December 31, 2015.
	2) Note Payable to the West Virginia Economic Development Authority (“WVEDA”)
	In August 2009, the Company obtained a 10-year loan in the amount of $242,631 from the WVEDA. The note bears interest at 4% providing for 120 monthly principal and interest payments of $2,457 through August 2019, at which time the note is due and payable. The note is secured by 50% of equipment costing $569,812. As of December 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the WVEDA approved a deferral of principal and interest until April 2, 2015.
	3) Note Payable to the West Virginia Infrastructure and Jobs Development Council (“WVIJDC”)
	In August 2009, the Company obtained a 10-year loan in the amount of $242,630 from the WVIJDC. The note bears interest at 3.25% providing for 120 monthly principal and interest payments of $2,371 through August 2019, at which time the note is due and payable. The note is secured by 50% of equipment costing $569,812. As of December 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the WVIJDC approved a deferral of principal and interest until December 31, 2015.
	4) Note Payable to the West Virginia Economic Development Authority (“WVEDA”)
	In October 2010, the Company obtained a 10-year note in the amount of $900,000 from the WVEDA. The note bears interest at 3.26% providing for 120 monthly principal and interest payments of $8,802 through October 2020, at which time the note is due and payable. The note is secured by equipment costing $997,248. As of December 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the WVEDA approved a deferral of principal and interest until April 2, 2015.
	5) Note Payable to the West Virginia Infrastructure & Jobs Development Council (“WVIJDC”)
	In December 2010, the Company obtained a 10-year note in the amount of $900,000 from the WVIJDC. The note bears interest at 3.25% providing for 120 monthly principal and interest payments of $8,781 through December 2020, at which time the note is due and payable. The note is secured by equipment costing $1,098,249. As of December 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the WVIJDC approved a deferral of principal and interest until December 31, 2015.
	6) Convertible Promissory Note Payable to the West Virginia Jobs Investment Trust Board (“WVJITB”)
	In March 2012, the Company issued an 18-month note in the amount of $290,000 from the WVJITB. The note bears interest at 6% providing for monthly interest-only payments starting April 2012 through August 2013, then final interest and principal payments due September 2013. The note has an adjustable conversion price, initially $2.00 per share, and includes a stock warrant for 72,500 shares (see Note 9, Stock Warrants). On December 13, 2013, the Company and the WVJITB entered into a Loan Modification Agreement whereby the maturity date changed from September 14, 2013 to $100,000 due on March 15, 2014 and the remaining $190,000 due on June 15, 2014. The WVJITB and the Company signed three addendums to the note extending the maturity date and deferring interest and principal payments until March 2, 2015. During 2014, the Company made interest only payments through October 31, 2014. On February 2, 2015, the Company and WVJITB entered into a Loan Modification Agreement whereby the interest payable for the periods of October 31, 2014 through June 30, 2015 would be due on June 30, 2015. The maturity date of the loan was also modified and extended to December 31, 2015. C.  Andrew Zulauf, an executive member of the WVJITB, is a board member of the Company.
	7) Convertible Promissory Note Payable to the West Virginia Jobs Investment Trust Board (“WVJITB”)
	In April 2012, the Company issued a 3-month note in the amount of $400,000 from the WVJITB. The note bears interest at 10% providing for monthly interest-only payments starting May 2012 through June 2012, then final interest and principal payments due July 2012. The note includes a stock warrant for 88,889 shares (see Note 9, Stock Warrants). The WVJITB and the Company have signed several addendums to the note extending the maturity date and reducing the price of converting into common shares to $0.50 per share. The WVJITB further extended the maturity date until November 29, 2013, with a $100,000 principal payment due on or before November 15, 2013. The Company repaid the $100,000 as agreed, which reduced the principal outstanding balance to $300,000. The WVJITB and the Company signed four addendums to the note extending the maturity date and deferring interest and principal payments until March 2, 2015. During 2014, the Company made interest only payments through October 31, 2014. On February 2, 2015, the Company and WVJITB entered into a Loan Modification Agreement whereby the interest payable for the periods of October 31, 2014 through June 30, 2015 would be due on June 30, 2015. The maturity date of the loan was also modified and extended to December 31, 2015. C. Andrew Zulauf, an executive member of the WVJITB, is a board member of the Company.
	8) Convertible Promissory Note Payable to the West Virginia High Technology Consortium Foundation (“WVHTCF”)
	In May 2012, the Company issued a 30-month note in the amount of $200,000 from the WVHTCF. The note bears interest at 8% providing for 25 monthly principal and interest payments of $9,001 starting December 2012 through November 2014, then final interest and principal payments due December 2014. The conversion price is $0.50 per share. The note is secured by 50% of equipment costing $447,320. As of December 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the West Virginia High Technology Consortium Foundation approved a deferral of principal and interest until March 2, 2015.
	9) Note Payable to the West Virginia Economic Development Authority (“WVEDA”)
	In June 2012, the Company issued a 10-year note in the amount of $200,000 from the WVEDA. The note bears interest at 2% providing for 120 monthly principal and interest payments of $1,840 through June 2022, at which time the note is due and payable. The note is secured by 50% of equipment costing $447,320. As of December 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the West Virginia Economic Development Authority approved a deferral of principal and interest until April 2, 2015.
	10) Capital Leases
	From time to time, in the normal course of business, the Company enters into capital leases to finance equipment. As of December 31, 2014, the Company had four capital lease obligations outstanding with imputed interest rates ranging from 5.96% to 6.11%. The leases require 30-60 monthly payments and begin to expire in May 2015 through October 2019. These leases are secured by equipment with an aggregate cost of $1,095,751. As of December 31, 2014, the Company was in arrears on one of these leases.
	Total debts outstanding are as follows:
				December 31, 2014		December 31, 2013
	1)	Note Payable to the WVDO		$	99,365	$	123,744
	2)	Note Payable to the WVEDA			141,369		147,306
	3)	Note Payable to the WVIJDC			139,128		145,078
	4)	Note Payable to the WVEDA			617,767		639,085
	5)	Note Payable to the WVIJDC			630,738		651,913
	6)	Note Payable to the WVJITB			290,000		290,000
	7)	Note Payable to the WVJITB			300,000		300,000
	8)	Note Payable to the WVHTCF			69,888		95,178
	9)	Note Payable to the WVEDA			166,258		170,932
	10)	Capital leases			820,524		71,077
		Total			3,275,037		2,634,313
		Less: current portion			-1,457,800		-1,054,053
		Long-term portion		$	1,817,237	$	1,580,260
	Future required minimum principal repayments over the next five years are as follows:
	Year ending December 31:	Future required minimum principal repayments
	2014 (payments in arrears)	$	297,244
	2015		1,160,556
	2016		562,860
	2017		441,038
	2018		292,163
	2019& Thereafter		521,176
	Total	$	3,275,037

Common_Stock

Common Stock	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Common Stock [Text Block]	8. Common Stock
	The Company is authorized to issue a total of 210,000,000 of shares of stock, of which 200,000,000 shares are designated Common Stock and 10,000,000 shares are designated Preferred Stock.
	Common Stock – par value of $.0001 per share with one vote in respect of each share held. Holders of Common Stock do not have cumulative voting rights. The members of the Board are elected by the affirmative vote of the holders of a majority of the Company’s outstanding Common Stock. Common Stock issues during 2013 are as follows:
		# Shares		Par		Price		Gross		Value of		Par		Additional
		Issued		Value		Per		Proceeds		Services		Value		Paid in
						Share				Obtained				Capital (1)
	December 31, 2012 Balance		31,879,247	$	0.0001		Various	$	37,467,400	$	529,138	$	3,188	$	37,993,350
	Issuance of stock (2)		21,164,846		0.0001		0.5		10,582,423		-		2,116		10,580,307
	Issuance of stock (3)		575,000		0.0001		0.5		-		287,500		57		287,443
	Issuance of stock (3)		6,247		0.0001		2		-		12,494		1		12,493
	Issuance of stock (4)		527,500		0.0001		Various		-		-		53		-53
	Issuance of stock (5)		11,289,895		0.0001		0.5		5,644,948		-		1,130		5,643,818
	Total December 31, 2013		65,442,735					$	53,694,771	$	829,132	$	6,545	$	54,517,358
	(1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
	(2) Of the shares issued, 10,897,946 shares contained an anti-dilution provision expiring five years from date of issuance, 10,218,900 shares contained an anti-dilution provision that expired on 12/31/2013, and 48,000 shares did not contain an anti-dilution provision.
	(3) Shares issued for services performed.
	(4) Shares issued under anti-dilution provision.
	(5) Shares issued upon the conversion of convertible debentures. Of the total shares issued, 4,626,696 shares contained an anti-dilution provision expiring five years from date of issuance while 6,663,199 shares did not contain an anti-dilution provision.
	Common Stock issues during 2014 are as follows:
	Common Stock	# Shares		Par		Price		Gross		Value of		Par		Additional
		Issued		Value		Per		Proceeds		Services		Value		Paid in
						Share				Obtained				Capital (1)
	December 31, 2013 Balance		65,442,735		0.0001		Various	$	53,694,771	$	829,132	$	6,545	$	54,517,358
	Issuance of stock (2)		1,112,348		0.0001		Various		-		985,541		111		985,430
	Stock options exercised (3)		25,000		0.0001	$	0.55		13,750		-		2		13,748
	Stock warrants exercised (4)		8,517		0.0001	$	1.77		-		-		1		-1
	Total December 31, 2014		65,588,600					$	53,708,521	$	1,814,673	$	6,659	$	55,516,535
	(1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
	(2) Shares issued for services performed and does not contain an anti-dilution provision
	(3) Shares issued for exercised stock options and does not contain an anti-dilution provision
	(4) Shares issued under cashless stock warrant exercise and does not contain an anti-dilution provision

Preferred_Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Preferred Stock [Text Block]	9. Preferred Stock
	Preferred Stock – par value of $.0001 per share with one vote in respect of each share held. The Company is authorized to issue Preferred Stock in one or more series and containing such rights, privileges and limitations, including voting rights, dividend rates, conversion privileges, redemption rights and terms, redemption prices and liquidation preferences, as the Board may, from time to time, determine. No shares of the Preferred Stock were issued prior to 2014.
	Preferred Stock	# Shares		Par		Price		Gross		Par		Additional
		Issued		Value		Per		Proceeds		Value		Paid in
						Share						Capital (1)
	December 31, 2013 Balance		-		-		-	$	-	$	-	$	-
	Issuance of stock (2)		2,264,238		0.0001	$	2		4,528,476		227		4,528,249
	Conversion of convertible debt (2)		1,073,487		0.0001	$	2		2,146,976		107		2,146,869
	Total December 31, 2014		3,337,725					$	6,675,452	$	334	$	6,675,118
	(1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
	(2) Shares issued contain an anti-dilution provision expiring upon the conversion to common stock.
	During 2014, the Company sold units of preferred stock consisting of 50,000 shares of Series A convertible Preferred Stock and a 3 year warrant to purchase 200,000 shares of Common Stock at an exercise price of $0.375 per share. Each share of Preferred Stock has a stated value equal to $2.00. The Preferred Stock will automatically convert into shares of Common Stock determined by dividing the stated value by $0.25 per share on February 17, 2015. Under certain circumstances, the holders of the Preferred Stock have voluntary conversion rights, are entitled to receive stock dividends at the rate of 6.0% per annum and shall be entitled to certain anti-dilution protections. As of December 31, 2014, the Preferred Stock is potentially convertible into 27,125,016 shares of Common Stock.

Stock_Options_and_Stockbased_C

Stock Options and Stock-based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options and Stock Based Compensation [Text Block]	10. Stock Options and Stock-based Compensation
	In 2002, the Board adopted the 2002 Equity Incentive Plan (“the 2002 Plan”) that governed equity awards to employees, directors and consultants of the Company. Under the Plan, 450,000 shares of common stock were reserved for issuance. From 2006 through 2012, the 2002 Plan was amended several times to increase the total number of shares authorized under the 2002 Plan to 4,150,000 shares. During the first quarter 2013, the Board adopted the 2013 Equity Incentive Plan (the “2013 Plan”) and together with the 2002 Plan (the “Plans”) governs the equity awards to employees, directors and consultants of the Company. Under the 2013 Plan, an additional 5,000,000 shares of common stock has been reserved for issuance. On June 18, 2013, the 2013 Plan was approved by holders of a majority of the issued and outstanding shares of common stock of the Company.
	The types of awards permitted under the Plan include qualified incentive stock options (ISO) and non-qualified stock options (NQO), and restricted stock. Each option shall be exercisable at such times and subject to such terms and conditions as the Board may specify. Stock options generally vest over four years and expire no later than ten years from the date of grant.
	A summary of stock option activity is as follows:
			Shares			Weighted Average			Weighted Average Remaining
						Exercise Price			Contractual Life (in years)
	Outstanding at December 31, 2012			3,864,750		$	1.42			4
	Granted			1,768,000		$	0.55
	Exercised			-			-
	Cancelled or expired			-550,000		$	1.47
	Outstanding at December 31, 2013			5,082,750		$	1.11			7.02
	Granted			2,404,500		$	0.55
	Exercised			-25,000		$	0.55
	Cancelled or expired			-442,500		$	1.11
	Outstanding at December 31, 2014			7,019,750		$	0.92			6.69
	Exercisable at December 31, 2013			4,005,583		$	1.2			6.52
	Exercisable at December 31, 2014			4,596,467		$	1.11			5.95
	The following table summarizes information about stock options at December 31, 2014:
				Options Outstanding								Options Exercisable
	Exercise Price			Outstanding			Weighted Average			Weighted		Exercisable		Weighted
							Remaining			Average				Average
							contractual life (in			Exercise				Exercise Price
							years)			Price
	$	0.5			159,000								133,625
	$	0.55			3,890,000								1,525,217
	$	0.8			320,000								320,000
	$	1.25			310,000								310,000
	$	1.5			2,126,000								2,092,875
	$	2			214,750								214,750
		$0.50 - $2.00			7,019,750			6.69		$	0.92		4,596,467	$	1.11
	At December 31, 2014, the total aggregate intrinsic value for options currently exercisable and options outstanding was $0. These values represent the total pre-tax intrinsic value based on the estimated fair value of the Company’s stock price of $0.39 as of December 31, 2014. During the year ended December 31, 2014, 25,000 shares were exercised, whereas no shares were exercised during the year ended December 31, 2013.
	The following table summarizes the activity of the Company’s stock options that have not vested for the year ended December 31, 2014:
			Shares			Weighted Average
						Grant-date Fair Value
	Nonvested at December 31, 2012			872,333		$	0.441
	Granted			807,292		$	0.219
	Forfeited			-550,000		$	0.675
	Vested			-52,458		$	0.894
	Nonvested at December 31, 2013			1,077,167		$	0.467
	Granted			1,986,145		$	0.207
	Forfeited			-259,062		$	0.513
	Vested			-380,967		$	0.734
	Nonvested at December 31, 2014			2,423,283		$	0.258
	The fair value of non-vested options to be recognized in future periods is $478,912, which is expected to be recognized over a weighted average period of 1.8 years. The total fair value of options vested during the year ended December 31, 2014 was $288,995 compared to $477,353 for the year ended December 31, 2013.
	Stock-based compensation expense is as follows:
			Year ended
			December 31, 2014			December 31, 2013
	Selling, general, and administrative expense		$	251,101		$	783,171
	Research and development expense			37,894			89,796
	Total stock-based compensation expense		$	288,995		$	872,967
	The weighted average grant-date fair value of options granted during the year ended December 31, 2014 was $0.207 and for the year ended December 31, 2013 was $0.219 per option.
	The fair value of the option grants was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions:
		Year ended
			December 31, 2014			December 31, 2013
	Risk-free interest rate			1.91	%		1.56	%
	Volatility factor			70.03	%		73.56	%
	Weighted average expected life (in years)			7			7
	Dividend rate			0	%		0	%
	The Company utilizes a peer group to estimate its expected volatility assumptions used in the Black-Scholes option-pricing model. The Company completed an analysis and identified four similar companies considering their industry, stage of life cycle, size, and financial leverage. Given the Company’s limited history with stock options, the Company’s expected term is based on an average of the contractual term and the vesting period of the options (the SAB 110 “Simplified” method).

Stock_Warrants

Stock Warrants	12 Months Ended
	Dec. 31, 2014
Stock Warrants [Abstract]
Stock Warrants [Text Block]	11. Stock Warrants
	From 2008 through 2014, the Company issued warrants mostly in connection with common and preferred stock issuances. The warrants are exercisable for one or five years from date of issuance. The warrant allows the holder to purchase shares of common stock. The exercise price is $0.375 to $2.25 per share.
	During 2013, the Company issued warrants mostly in connection with common stock issuances. The warrants are exercisable one or five years from date of issuance. The exercise price is $0.50 to $1.10 per share. The warrant allows the holder to purchase shares of common stock, and contains anti-dilution provisions that adjust the exercise price if certain equity instruments are issued (subject to certain exceptions) at a value below the then-existing exercise price of the warrants. The anti-dilutive provisions have an expiration term of either one or five years from date of issuance. The anti-dilutive provision on 7,592,400 warrants expired on December 31, 2013.
	As of December 31, 2014, warrants to purchase 53,112,193 shares of common stock were outstanding and exercisable. The Company recognized a total of $192,421 in interest expense and $49,921 in consulting services during the year ended December 31, 2014 and $537,137 in placement agent services for the year ended December 31, 2013 as a result of issuing an aggregate of 3,720,323 warrants earned in 2014.
			Shares			Weighted Average			Weighted Average Remaining
						Exercise			Contractual Life
						Price			(in years)
	Outstanding at December 31, 2013			52,705,614		$	1.3			2.58
	Granted			18,673,721		$	0.5			3.25
	Exercised			-22,500			-
	Cancelled or expired			-18,244,642		$	0.72
	Outstanding at December 31, 2014			53,112,193		$	0.98			3.27
	The following table summarizes information about stock warrants at December 31, 2014:
	Warrants Outstanding
	Exercise Price			Outstanding			Weighted Average Remaining			Weighted Average
							Contractual Life (in years)			Exercise Price
	$	0.375			13,350,898
	$	0.75			11,065,144
	$	0.8			1,415,000
	$	1.1			18,886,850
	$	1.12			263,750
	$	2			6,735,842
	$	2.2			98,320
	$	2.25			1,296,389
	$	0.375 - $2.25			53,112,193			3.27		$	0.98

Treasury_Stock

Treasury Stock	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Treasury Stock [Text Block]	12. Treasury Stock
	Treasury stock is accounted for using the par value method and is constructively cancelled when received.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	13. Income Taxes
	The provision for income taxes, if any, is comprised of current and deferred components. The current component, if any, presents the amount of federal and state income taxes that are currently reportable to the respective tax authorities and is measured by applying statutory rates to the Company’s taxable income as reported in its income tax returns. The Company has evaluated its income tax positions in accordance with FASB ASC 740. There were no changes to unrecognized tax benefits during 2013. The tax years 2010 through 2013 remain open to review by various taxing authorities.
	ASC Topic 740, Income Taxes defines the confidence level that a tax position must meet in order to be recognized in the financial statements. Accordingly, we have assessed uncertain tax positions in each of the tax jurisdictions in which we have operations and account for the related financial statement implications. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in income tax expense.
	Significant management judgment is required in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded in connection with the deferred tax assets.
	The Company provides for a full valuation allowance against the deferred tax asset. Net operating loss carryforwards start to expire beginning 2021 for both federal and state purposes. The net operating tax loss carryforward totals approximately $59,800,000 and $50,000,000 at December 31, 2014 and December 31, 2013, respectively.
	We have recorded a full valuation allowance of $24,352,000 and $20,458,000 as of December 31, 2014 and 2013, respectively, due to uncertainties related to our ability to utilize the Company’s deferred tax assets, primarily consisting of certain net operating losses carried forward. The valuation allowance is based on management’s current estimates of taxable income for the jurisdictions in which we operate and the period over which the deferred tax assets will be recoverable.
		December 31, 2014		December 31, 2013
	Current deferred income tax asset:
	Tax net operating loss carry forward	$	23,305,265	$	19,522,559
	Tax-deferred stock option expense		1,047,309		935,666
	Research and development expense		-		-
	Total current deferred income tax asset		24,352,574		20,458,225
	Valuation Allowance		-24,352,574		-20,458,225
	Net deferred income tax asset	$	-	$	-
	In the event that actual results differ from these estimates, or these estimates are adjusted in future periods, and realization of these deferred tax assets for which the valuation allowance has been provided occur, the provision for income taxes may decrease, raising income and positively impacting the Company’s financial position.

Lease_Commitments

Lease Commitments	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Lease Commitments [Text Block]	14. Lease Commitments
	The Company leases its facilities under operating leases beginning a) February 2005 and extended through December 2012 with a month-to-month to lease subsequent to the lease term period and b) April 2012 through March 2017. The Company also has one equipment operating lease with a term of five years.
	Future minimum rental payments are as follows for the year ending December 31, 2014:
	Year ending	Future minimum rental payments
	2014 (payment in arrears)	$	32,386
	2015	$	172,428
	2016	$	172,428
	2017	$	46,707
	2018	$	4,800
	2019 & Thereafter	$	4,000
	Rent expense totals $371,198 for the year ended December 2014 and $435,863 for 2013.

Retirement_Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2014
Postemployment Benefits [Abstract]
Retirement Plan [Text Block]	15. Retirement Plan
	The Company provides a 401(k) Profit Sharing Plan for elective deferrals whereby participants can defer up to 100% of their wages not to exceed a maximum dollar amount determined by the Federal Government each year. The Company, at its discretion, can make matching contributions to the Plan. The Company may also make qualified non-elective contributions to participants who are not highly compensated employees. All employees meeting age and hours of service requirements are eligible to participate in the Plan after completing one year of service. Participants become vested in employer contributions on a graduated scale with full vesting after five years. No Company contributions have yet been made.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Legal Matters and Contingencies [Text Block]	16. Commitments and Contingencies
	Legal Proceedings
	The Company currently is not a party to any material legal proceeding and has no knowledge of any material legal proceeding contemplated by any governmental authority or third party. The Company may be subject to a number of claims and legal proceedings which, in the opinion of our management, are incidental to normal business operations. In managements’ opinion, although final settlement of these claims and suits may impact the financial statements in a particular period, they will not, in the aggregate, have a material adverse effect on the Company’s financial position, cash flows or results of operations.
	Indemnity of Directors and Officers
	As permitted under Delaware law and required by corporate by-laws, the Company indemnifies and holds harmless its directors and officers for certain events or occurrences while the director or officer is or was serving in such capacity. The maximum potential amount of future payments that could be required under these indemnification obligations is unlimited; however, the Company maintains a Directors and Officers liability insurance policy that enables it to recover a portion of any future amounts paid with a limit of liability of $5,000,000.  The Company may incur an additional liability if indemnity for more than the limit of liability occurred, and such liability may have a material adverse effect on our financial position, cash flows and results of operations. As there were no known or pending claims, the Company has not accrued a liability for such claims as of December 31, 2014.
	Warranty Costs
	The Company provides for a one-year warranty with the sale of its LAESI instrument. All other product warranties are 90 days from the date of delivery of the goods. As the Company does not currently have sufficient historical data on warranty claims, the Company's estimates of anticipated rates of warranty claims and costs are primarily based on comparable industry metrics. The Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its product. During the year ended December 31, 2014, the Company recorded accrued warranty expense of $50,000 compared to $81,250 during the year ended December 31, 2013.
	University License Agreements
	The Company has agreements with universities related to in-licensed technologies as follows:
	AGREEMENT WITH WEST VIRGINIA UNIVERSITY (WVU)
	The Company has entered into a License and Exclusive Option to License Agreement with the West Virginia University Research Corporation, a nonprofit West Virginia corporation (“WVURC”) acting for and on behalf of WVU. Under the terms of this Agreement, the WVURC has granted the Company an exclusive option to license technology from the laboratories of certain WVU principal investigators in the field of protein discovery for therapeutic, diagnostic and all other commercial fields worldwide.
	Under the terms of this Agreement, the Company pays expenses for the preparation, filing and prosecution of related patent applications, and the Company will pay royalties on the net revenue resulting from the sale of products and services that utilize the WVU subject technology.
	AGREEMENT WITH GEORGE WASHINGTON UNIVERSITY (GWU)
	In December 2008, the Company entered into an Exclusive License Agreement with George Washington University (Washington D.C.) for technology developed in the laboratory of Dr. Akos Vertes Ph.D., Professor of Chemistry, Professor of Biochemistry & Molecular Biology, Founder and Co-Director of the W.M. Keck Institute for Proteomics Technology and Applications, the Department of Chemistry, who is a science advisor to the Company. The technology field is LAESI - laser ablation electrospray ionization, a new method of bioanalytical analysis that enables high throughput biomolecule characterization.
	Under the terms of the license agreement, the Company has the exclusive, worldwide rights to commercialize the technology. The Company is obligated to pay expenses for the preparation, filing and prosecution of related patent applications, and the Company will pay royalties on the net revenues resulting from the sale of products and services that utilize the GWU subject technology. During the year ended December 31, 2014, the Company recorded royalty expenses of approximately $45,500 compared to $34,700 as of December 31, 2013. The Company made payments to GWU in the amount of $50,900 in 2014 and the outstanding royalty balance due December 31, 2014 was approximately $29,300.
	In November 2012, the Company entered into a Patent License Agreement with George Washington University (Washington D.C) for technology developed in the laboratory of Akos Vertes Ph.D. The technology field is Laser Desorption/Ionization and Peptide Sequencing on Laser-Induced Silicon Microcolumn Arrays (Matrix) and Nanophotonic Production, Modulation and Switching of Ions by Silicon Microcolumn Arrays.
	Under the terms of the license agreement, the Company has an exclusive, worldwide license to make, have made, use, import, offer for sale and sell the licensed products. The Company is obligated to pay a license initiation fee of $25,000 and a minimum license diligence resources of $12,500 in year two and $20,000 each year thereafter to develop and commercialize the products, $30,000 milestone payment upon the first sale of a licensed product, and royalties will be 7% of the net sales of licensed products and 5% of the net sales of combination products for combined cumulative net sales up to $50 million. Thereafter, royalties reduce to 6% and 4%, respectively, after taking into account quarterly minimum royalties of $1,500 for the first four quarters after the first sale of a licensed product, $2,500 for the next four quarters, $3,500 for the next four quarters and $6,000 for each succeeding quarter.
	AGREEMENT WITH OMICS2IMAGE
	In 2014, the Company entered into an agreement with Omics2Image related to the “Next Generation Ambient Imaging Mass Spectrometry for (Bio)polymers and Smart Materials” (“COAST Project”). The Company has committed to fund 60,000 Euros or $77,000 related to the COAST Project over the next twelve month period. Omics2Image agrees to evenly share the value gained from the efforts outlined within the scope of the COAST Project, which may include new intellectual property and the development of a commercial, integrated instrument system. As of December 31, 2014, the Company had made one payment of 20,000 Euros or $25,500 to Omics2Image.
	Engineering and Design Services
	The Company has engaged Dynamic Manufacturing LLC, a new contract manufacture to produce ten LAESI units. As of December 31, 2014, the Company had received five LAESI units from Dynamic. As of December 31, 2014, the Company had approximately $373,300 in outstanding commitments with Dynamic as well as approximately $124,000 in payables due to Dynamic.
	The Company had approximately $21,900 in outstanding commitments with Bridger Photonics for lasers related to the LAESI technology. As of December 31, 2014, the Company owed approximately $59,000 in payables due to Bridger.
	Capital Expenditures
	In December 2014, the Company made a down payment of $104,524 on a mass spectrometer with Thermo Fisher Scientific. The equipment will be built and received in 2015. The Company will finance the remaining purchase price of the equipment under a capital lease structure. As of December 31, 2014, the Company had about $326,000 in outstanding commitments with Thermo. At December 31, 2014, the Company had no expenses owed to Thermo.
	Additionally, the Company made a down payment of $26,266 on a nitrogen generator with Navitas Lease Corp. The equipment will be built and received in 2015. The Company will finance the remaining purchase price of the equipment under a capital lease structure. As of December 31, 2014, the Company had about $68,000 in outstanding commitments with Navitas. At December 31, 2014, the Company had no expenses owed to Navitas.

Evaluation_of_Subsequent_Event

Evaluation of Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	17. Evaluation of Subsequent Events
	Issuance of Preferred Stock
	On February 12, 2015, the Company received $100,000 in aggregate gross cash proceeds from 2 accredited investors in connection with the sale of approximately 1units (each a “Unit” and collectively, the “Units”) pursuant to the terms and conditions of a Subscription Agreement (the “Subscription Agreement”) and Unit Purchase Agreement (the “Purchase Agreement”) by and among the Company and each of the purchasers (the “Purchasers”) thereto. Each Unit consists of (i) 50,000 shares of Series A convertible preferred stock, par value $0.0001 per share (the “Preferred Stock”), (ii) and a 3 year warrant to purchase 200,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) at an exercise price of $0.375 per share (the “Investor Warrants”) for an aggregate of 50,000 shares of the Company’s preferred stock and Investor Warrants to purchase an aggregate of 200,000 shares of the Company’s common stock issued at the Initial Closing in connection with the cash proceeds received.
	Each share of Preferred Stock has a stated value equal to $2.00, subject to increase (the “Stated Value”). The Preferred Stock will automatically convert into shares of Common Stock determined by dividing the Stated Value by $0.25 per share on February 17, 2015. Under certain circumstances, the holders of the Preferred Stock have voluntary conversion rights, are entitled to receive dividends at the rate of 6.0% per annum and shall be entitled to certain anti-dilution protections.
	In connection with the Initial Closing, the Company also paid to a FINRA registered broker dealer that acted as the placement agent (the “Placement Agent”) an aggregate of $10,000 in cash compensation, representing fees and an expense allowance. In addition, the Company agreed to issue a warrant (the “Placement Agent Warrant”) to purchase an aggregate of 60,000 shares of Common stock to the Placement Agent (or its designees).
	Advances from Stockholders
	Subsequent to the Balance Sheet date, the Company received advances equal to an aggregate of $298,000 from certain current directors and related parties. No terms of repayment have been specified on the aforementioned advances as of the filing date.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Protea Biosciences Group, Inc. and its wholly-owned subsidiary, Protea Biosciences, Inc. All material accounts and transactions have been eliminated in consolidation. During 2014, the Company sold Proteabio Europe but retains continued involvement through an equity method investment in AzurRx BioPharma, Inc., the Buyer of Proteabio Europe. (See Note 3 Subsidiary Sale) As the sale was not fully consummated due to an outstanding contingency, the transaction was not recognized until December 12, 2014. As such, the results of Proteabio Europe are consolidated into the Company’s financial statements for the year ended December 31, 2014.
Liquidity Disclosure [Policy Text Block]	Going Concern
	The Company’s financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has funded its activities to date almost exclusively from debt and equity financings. The Company will continue to require substantial funds to advance the research and development of its core technologies and to develop new products and services based upon its proprietary protein recovery and identification technologies.
	Management intends to meet its operating cash flow requirements primarily from the sale of equity and debt securities. The Company seeks additional capital through sales of equity securities or convertible debt and, if appropriate, to pursue partnerships to advance various research and development activities. The Company may also consider the sale of certain assets, or entering into a transaction such as a merger with a business complimentary to theirs.
	While the Company believes that it will be successful in obtaining the necessary financing to fund its operations, they have no committed sources of funding and are not assured that additional funding will be available to them. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.
Use of Estimates, Policy [Policy Text Block]	Estimates and Assumptions
	The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	The Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. The Company has cash on deposit at banks that may exceed the federally-insured limits at times.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Trade Accounts Receivable
	Trade accounts receivable are reported at the amount management expects to collect from outstanding balances. Differences between the amount due and the amount management expects to collect are reported in the statement of operations of the year in which those differences are determined, with an offsetting entry to a valuation allowance for trade accounts receivable. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable. The Company performs ongoing credit evaluations of its customers and generally does not require collateral.
	The Company maintains allowances for doubtful accounts based on management’s analysis of historical losses from uncollectible accounts and risks identified for specific customers who may not be able to make required payments. If the financial condition of customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. An allowance of $3,000 was deemed necessary as of December 31, 2014 and $4,000 as of December 31, 2013.
Equity Method Investments, Policy [Policy Text Block]	Equity Method Investments
	The Company’s 33% interest in AzurRx BioPharma, Inc. (“AzurRx”) is accounted for on the equity method. AzurRx is a private biotechnology company formed to focus on the development of the early stage pharmaceutical assets of ProteaBio Europe.  Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee Company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee Company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Consolidated Balance Sheets and Consolidated Statements of Income; however, the Company’s share of the earnings or losses of the Investee Company is reflected in the caption “Income from equity method investments” in the Consolidated Statements of Income. The Company’s carrying value in an equity method Investee company would be reflected in the caption “Equity method investments” in the Company’s Consolidated Balance Sheets.
Other Receivables and Other Noncurrent assets [Policy Text Block]	Other Receivables and Other Noncurrent assets
	Other receivables, which reflect amounts from non-trade activity and other noncurrent assets, consist of the following at:
			December 31, 2014			December 31, 2013
	French government R&D credit		$	-		$	400,379
	Other receivables			119,230			34,899
	Other receivables - current		$	119,230		$	435,278
	Deposits		$	136,693		$	23,249
	Other noncurrent assets		$	136,693		$	23,249
Inventory, Policy [Policy Text Block]	Inventory
	Inventory represents finished goods and work in progress. Finished goods and work in progress consist primarily of specifically identifiable items that are valued at the lower of cost or fair market value using the first-in, first-out (FIFO) method. Inventory consists of the following at:
			December 31, 2014			December 31, 2013
	Finished goods		$	18,739		$	360,607
	Work in progress			142,562			104,727
	Total Inventory		$	161,301		$	465,334
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
	Expenditures for maintenance and repairs are charged to expense and the costs of significant improvements that extend the life of underlying assets are capitalized.
	Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows:
	Laboratory Equipment	5 - 10 years
	Computers	5 years
	Leasehold improvements	Life of lease
	Software	3 years
	Property and equipment consists of the following at:
			December 31, 2014			December 31, 2013
	Lab equipment		$	7,313,979		$	6,620,662
	Computer equipment			540,814			563,976
	Office equipment			229,785			248,490
	Leasehold improvements			434,304			477,682
				8,518,882			7,910,810
	Accumulated depreciation			-5,558,792			-5,024,634
	Property and equipment, net		$	2,960,090		$	2,886,176
	Depreciation expense is charged to either research and development or selling, general and administrative  expenses and totals $825,780 in 2014 and $844,888 in 2013.
	The Company evaluates the potential impairment of property and equipment whenever events or changes in circumstances indicate that the carrying value of a group of assets may not be recoverable. An impairment loss would be recognized when the carrying amount of the asset group exceeds the estimated undiscounted future cash flows expected to be generated from the use of the asset group and its eventual disposition. The amount of impairment loss to be recorded is measured as the excess of the carrying value of the asset group over its fair value. Fair value is generally determined using a discounted cash flow analysis or market prices for similar assets.
Revenue Recognition, Deferred Revenue [Policy Text Block]	Revenue Recognition
	We follow the provisions of FASB ASC 605, “Revenue Recognition”. We recognize revenue of products when persuasive evidence of a sale arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred /title has passed, and collectability of the sales price is reasonably assured. The Company recognizes revenue from the sale of its ProteaPlot™ software when bundled with the LAESI platform, which facilitates operating the instrument and storage and display of datasets. The Company also recognizes revenue of standalone sales of ProteaPlot™, which generally consists of additional user licenses. Revenue is recognized once the title is passed to the customer.
	We account for shipping and handling fees and costs in accordance with the provisions of FASB ASC 605-45-45, “Revenue Recognition – Principal Agent Considerations”, which requires all amounts charged to customers for shipping and handling to be classified as revenues. Shipping and handling costs charged to customers are recorded in the period the related product sales revenue is recognized.
	Regarding short-term service contracts, the majority of these service contracts involve the processing of imaging and bioanalytical samples for pharmaceutical and academic/clinical research laboratories. These contracts generally provide for a fixed fee for each method developed or sample processed and revenue is recognized when the analysis is complete and a report is delivered.
	For longer-term contracts involving multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. We perform this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, we account for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) have standalone value to the customer, and the delivery or performance of the service(s) is probable and substantially in our control. Revenue on multiple revenue arrangements is recognized using a proportional method for each separately identified element. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or, if there is no predominant deliverable, upon delivery of the final element of the arrangement.
	Revenues from grants are based upon internal costs that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by the Company that is related to the grants. The Company has revenue from four major components: molecular information services, LAESI instrument platform, research products, and grants and other collaboration revenues. Revenue by component was as follows:
			Year Ended
			December 31, 2014			December 31, 2013
	Molecular Information Services		$	504,750		$	199,220
	LAESI Instrument Platform			743,250			651,584
	Research Products			400,141			372,688
	Grants and Other Collaborations			120,171			-
	Gross Revenue		$	1,768,312		$	1,223,492
	A small number of customers have accounted for a substantial portion of our revenues in 2014. Five customers represented 42% of gross revenues for the year ended December 31, 2014. The Company is not dependent on a limited number of customers for sale of its products and services.
Other Payables and Accrued Expenses [Policy Text Block]	Other Payables and Accrued Expenses
	Other payables and accrued expenses, which reflect amounts due from non-trade activity, consist of the following at:
			December 31, 2014			December 31, 2013
	Accrued expenses		$	31,104		$	653,047
	Accrued interest			201,844			39,911
	Accrued warranties			50,000			81,250
	Accrued payroll and benefits			219,973			286,979
	Unearned revenue			15,900			7,980
	Other payables and accrued expenses		$	518,821		$	1,069,167
Standard Product Warranty, Policy [Policy Text Block]	Warranty Costs
	The Company provides for a one-year warranty with the sale of its LAESI instrument. Additionally, the Company sells extended warranties for an additional cost. To date, the Company has not sold any extended warranties. All other product warranties are 90 days from the date of delivery of the goods. As the Company does not currently have sufficient historical data on warranty claims, the Company's estimates of anticipated rates of warranty claims and costs are primarily based on comparable industry metrics. The Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its product. During the year ended December 31, 2014, the Company recorded accrued warranty expense of $50,000 compared to $81,250 accrued warranty expense for the year ended December 31, 2013.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency
	Foreign currency adjustments resulting from international sales are reflected in accumulated other comprehensive income/loss.
Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block]	Advertising
	The Company follows the policy of charging the costs of advertising to expense as incurred.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Credit
	The Company follows the policy of charging the costs of research and development to expense as incurred. Research and Development expense disclosed on the Consolidated Statement of Operations is net of the French Government Research Credit, which was $379,737 in 2014 and $398,285 in 2013.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share
	Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Common share equivalents (which may consist of convertible preferred stock and dividends, options, warrants and convertible debt) are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 84,834,000 and 56,711,000 at December 31, 2014 and 2013, respectively.
Reclassification, Policy [Policy Text Block]	Reclassification
	Certain amounts have been reclassified in the presentation of the Consolidated Financial Statements for the year ended December 31, 2013 to be consistent with the presentation in the Consolidated Financial Statements for the year ended December 31, 2014.  This reclassification had no impact on previously reported net loss, cash flow from operations or changes in stockholder equity.
Income Tax, Policy [Policy Text Block]	Income Taxes
	Deferred income taxes are reported using the liability method. Deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation
	The Company follows the provisions of FASB ASC 718, “Stock-Based Compensation”. Stock-Based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period. Fair value of Company stock options is estimated using the Black-Scholes option-pricing model. The associated compensation expense is recognized on a straight-line basis over the requisite service period, net of estimated forfeitures.
	Estimating the fair value for stock options for each grant requires judgment, including estimating stock-price volatility, expected term, expected dividends and risk-free interest rates. The expected volatility rates are estimated based on the volatility of similar entities whose share information is publicly available. The expected term represents the average time that options are expected to be outstanding and is estimated based on the average of the contractual term and the vesting period of the options as provided in SEC Staff Accounting Bulletin #110 as the “simplified” method. The risk-free interest rate for periods approximating the expected term of the options is based on the U.S. Treasury yield curve in effect at the time of grant. Expected dividends are zero as the Company has no plans to issue dividends on common stock.
	Prior to becoming a public company, the Company used an index to calculate the expected volatility component of the fair value model. Subsequent to becoming a public company and due to a lack of trading history, the Company utilizes a peer group to estimate its expected volatility assumptions used in the Black-Scholes option-pricing model. The Company completed an analysis and identified four similar companies considering their industry, stage of life cycle, size, and financial leverage. (See Note 9, Stock Options and Stock-Compensation)
Derivatives, Embedded Derivatives [Policy Text Block]	Derivative Liabilities
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks; however, the Company has certain financial instruments that are embedded derivatives associated with capital raises and common stock purchase warrants. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 810-10-05-4 and 815-40.  This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date.  In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion or exercise, the derivative liability is marked to fair value at the conversion date and then the related fair value is reclassified to equity.
Fair Value Measurement, Policy [Policy Text Block]	Fair value of financial assets and liabilities – Derivative Instruments
	We measure the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.
	GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The three levels of inputs used to measure fair value:
	Level 1 – quoted prices in active markets for identical assets or liabilities.
	Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable.
	Level 3 – inputs that are unobservable (for example, the probability of a capital raise in a “binomial” methodology for valuation of a derivative liability directly related to the issuance of common stock warrants).
	The Company has entered into certain financial instruments and contracts such as, equity financing arrangements for the issuance of common stock, which include anti-dilution arrangements and detachable stock warrants that are i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are recorded as derivative liabilities at fair value at the issuance date. Subsequent changes in fair value are recorded through the statement of operations.
	The Company’s derivative liabilities are related to common stock issuances, detachable common stock purchase warrants (“warrants”) issued in conjunction with debt and common stock, or warrants issued to the placement agents for financial instrument issuances. We estimate fair values of the warrants that do contain “Down Round Protections” utilizing valuation models and techniques that have been developed and are widely accepted that take into account the additional value inherent in “Down Round Protection.” These widely accepted techniques include “Modified Binomial”, “Monte Carlo Simulation” and the “Lattice Model.” The “core” assumptions and inputs to the “Binomial” model are the same as for “Black-Scholes”, such as trading volatility, remaining term to maturity, market price, strike price, and risk free rates; all Level 2 inputs.  Fair value measurements are classified according to the lowest level input or value-driver that is significant to the valuation. A measurement may therefore be classified within Level 3 even though there may be significant inputs that are readily observable. However, a key input to a “Binomial” model (in our case, the “Monte Carlo Simulation”, for which we engaged an independent valuation firm to perform) is the probability of a future capital raise.  By definition, this input assumption does not meet the requirements for Level 1 or Level 2 outlined above; therefore, the entire fair value calculation is deemed to be Level 3 under accounting requirements due to this single Level 3 assumption. This input to the Monte Carlo Simulation model was developed with significant input from management based on its knowledge of the business, current financial position and the strategic business plan with its best efforts.
	As discussed above, financial liabilities are considered Level 3 when their fair values are determined using pricing models or similar techniques and at least one significant model assumption or input is unobservable.  For the Company, the Level 3 financial liability is the derivative liability related to the common stock and warrants that include “Down Round Protection” and they were valued using the “Monte Carlo Simulation” technique.  This technique, while the majority of inputs are Level 2, necessarily incorporates a Capital Raise Assumption which is unobservable and, therefore, a Level 3 input.
	A range of key quantitative assumptions related to the common stock and warrants issued during 2014 and 2013 are as follows:
			December 31, 2014
			Expected	Risk Free				Volatility				Probability of a Capital
			Life (Years)	Rate								Raise
	Derivative liabilities		5-Jan			1.38	%			77.86	%	100	%
			December 31, 2013
			Expected		Risk Free		Volatility				Probability of a Capital
			Life (Years)		Rate						Raise
	Derivative liabilities		5-Jan		0.13-1.75	%			83.3-88.3	%			100	%
	Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
	The Company’s derivative liabilities are related to common stock issuances, detachable warrants issued in conjunction with debt and common stock, or warrants issued to the placement agents for financial instrument issuances. The derivative liabilities measured at fair value on a recurring basis are summarized below:
			Fair Value Measurements at December 31, 2014
			Carrying Value			Level 1			Level 2			Level 3
	Derivative liabilities – common stock		$	88,871			-			-		$	88,871
	Derivative liabilities – warrants			65,187			-			-			65,187
	Total		$	154,058			-			-		$	154,058
			Fair Value Measurements at December 31, 2013
			Carrying Value			Level 1			Level 2			Level 3
	Derivative liabilities – common stock		$	558,799			-			-		$	558,799
	Derivative liabilities – warrants			64,788			-			-			64,788
	Total		$	623,587			-			-		$	623,587
	As a result of the 2014 Preferred Stock issuance, the Company has an obligation to issue 10,122,067 shares of Common Stock related to anti-dilution protection rights to various stockholders. As the Company had not issued these shares at December 31, 2014, the fair value of these shares, which was $1,771,362, was reduced from the derivative liability, and recorded as Common Stock to be issued in additional paid in capital as of December 31, 2014. The table below provides a summary of the changes in fair value of the derivative liabilities measured at fair value on a recurring basis:
			Year Ended December 31, 2014
			Derivative			Derivative			Total Fair Value
			liabilities -			liabilities -			Measurements
			Common Stock			Warrants			Using Level 3
									Inputs
	Beginning balance		$	558,799		$	64,788		$	623,587
	Issuance of warrants			-			2,550			2,550
	Anti-dilution shares to be issued			-1,771,362			-			-1,771,362
	Unrealized (gain) loss on derivative liabilities			1,301,434			-11,449			1,289,985
	Recognition of derivative liabilities			-			9,298			9,298
	Ending balance		$	88,871		$	65,187		$	154,058
			Year Ended December 31, 2013
			Derivative			Derivative			Total Fair Value
			liabilities -			liabilities -			Measurements
			Common Stock			Warrants			Using Level 3
									Inputs
	Beginning balance		$	-		$	-		$	-
	Issuance of warrants			-			45,685			45,685
	Unrealized (gain) loss on derivative liabilities			-257,846			-122,140			-379,986
	Recognition of derivative liabilities			816,645			141,243			957,888
	Ending balance		$	558,799		$	64,788		$	623,587
New Accounting Pronouncements, Policy [Policy Text Block]	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
	In April 2014, the FASB issued a standard that updated the guidance on Presentation of Financial Statements, and Property, Plant and Equipment. The amendments in this standard change the criteria for reporting discontinued operations for all public and nonpublic entities. The amendments also require new disclosures about discontinued operations and disposals of components of an entity that does not qualify for discontinued operations reporting. This guidance will become effective for all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years, and therefore will become effective for us as of the beginning of our 2015 fiscal year. The Company is evaluating the impact that this standard will have on its consolidated financial statements.
	In May 2014, the FASB issued a standard on revenue recognition that provides a single, comprehensive revenue recognition model for all contracts with customers.  The standard is principle-based and provides a five-step model to determine the measurement of revenue and timing of when it is recognized. The core principle is that a company will recognize revenue to reflect the transfer of goods or services to customers at an amount that the company expects to be entitled to in exchange for those goods or services. This standard is to be applied retrospectively and is effective for fiscal years beginning after December 15, 2016. The Company is evaluating the impact that this standard will have on its consolidated financial statements.
	In June 2014, the FASB issued authoritative guidance which eliminates the concept of a development stage entity. The incremental reporting requirements for presenting the development stage operations and cash flows since inception will no longer apply to development stage entities. The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 are to be applied retrospectively and are effective for fiscal years beginning after December 15, 2014. The Company has elected to early adopt this standard effective December 31, 2014 and removed all references to since inception values presented in the consolidated financial statements.
	In June 2014, the FASB issued authoritative guidance on stock compensation, which requires performance targets that affect vesting and can be achieved after the requisite service period, to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If achievement of the performance target becomes probable before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The amendments are effective for fiscal years beginning after December 15, 2015. The Company is evaluating the impact that this standard will have on its consolidated financial statements.
	In August 2014, the FASB issued authoritative guidance on going concern disclosures and financial statement presentation, which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). This standard provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the financial statement footnotes. This standard is effective for annual reporting periods ending after December 15, 2016, and to annual and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements and related disclosures.
	In November, 2014, the FASB issued ASU 2014-16, "Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force)." The ASU clarifies how current guidance should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of a host contract. The ASU is effective for fiscal years and interim periods beginning after December 15, 2015. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Trade and Other Receivables [Table Text Block]	Other receivables, which reflect amounts from non-trade activity and other noncurrent assets, consist of the following at:
			December 31, 2014			December 31, 2013
	French government R&D credit		$	-		$	400,379
	Other receivables			119,230			34,899
	Other receivables - current		$	119,230		$	435,278
	Deposits		$	136,693		$	23,249
	Other noncurrent assets		$	136,693		$	23,249
Schedule of Inventory, Current [Table Text Block]	Inventory
	Inventory represents finished goods and work in progress. Finished goods and work in progress consist primarily of specifically identifiable items that are valued at the lower of cost or fair market value using the first-in, first-out (FIFO) method. Inventory consists of the following at:
			December 31, 2014			December 31, 2013
	Finished goods		$	18,739		$	360,607
	Work in progress			142,562			104,727
	Total Inventory		$	161,301		$	465,334
Property Plant And Equipment Useful Life [Table Text Block]	Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows:
	Laboratory Equipment	5 - 10 years
	Computers	5 years
	Leasehold improvements	Life of lease
	Software	3 years
Property, Plant and Equipment [Table Text Block]	Property and equipment consists of the following at:
			December 31, 2014			December 31, 2013
	Lab equipment		$	7,313,979		$	6,620,662
	Computer equipment			540,814			563,976
	Office equipment			229,785			248,490
	Leasehold improvements			434,304			477,682
				8,518,882			7,910,810
	Accumulated depreciation			-5,558,792			-5,024,634
	Property and equipment, net		$	2,960,090		$	2,886,176
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Revenue by component was as follows:
			Year Ended
			December 31, 2014			December 31, 2013
	Molecular Information Services		$	504,750		$	199,220
	LAESI Instrument Platform			743,250			651,584
	Research Products			400,141			372,688
	Grants and Other Collaborations			120,171			-
	Gross Revenue		$	1,768,312		$	1,223,492
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Other payables and accrued expenses, which reflect amounts due from non-trade activity, consist of the following at:
			December 31, 2014			December 31, 2013
	Accrued expenses		$	31,104		$	653,047
	Accrued interest			201,844			39,911
	Accrued warranties			50,000			81,250
	Accrued payroll and benefits			219,973			286,979
	Unearned revenue			15,900			7,980
	Other payables and accrued expenses		$	518,821		$	1,069,167
Fair Value Inputs, Instruments Classified in Shareholders Equity, Quantitative Information [Table Text Block]	A range of key quantitative assumptions related to the common stock and warrants issued during 2014 and 2013 are as follows:
			December 31, 2014
			Expected	Risk Free				Volatility				Probability of a Capital
			Life (Years)	Rate								Raise
	Derivative liabilities		5-Jan			1.38	%			77.86	%	100	%
			December 31, 2013
			Expected		Risk Free		Volatility				Probability of a Capital
			Life (Years)		Rate						Raise
	Derivative liabilities		5-Jan		0.13-1.75	%			83.3-88.3	%			100	%
Fair Value, by Balance Sheet Grouping [Table Text Block]	The derivative liabilities measured at fair value on a recurring basis are summarized below:
			Fair Value Measurements at December 31, 2014
			Carrying Value			Level 1			Level 2			Level 3
	Derivative liabilities – common stock		$	88,871			-			-		$	88,871
	Derivative liabilities – warrants			65,187			-			-			65,187
	Total		$	154,058			-			-		$	154,058
			Fair Value Measurements at December 31, 2013
			Carrying Value			Level 1			Level 2			Level 3
	Derivative liabilities – common stock		$	558,799			-			-		$	558,799
	Derivative liabilities – warrants			64,788			-			-			64,788
	Total		$	623,587			-			-		$	623,587
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	The table below provides a summary of the changes in fair value of the derivative liabilities measured at fair value on a recurring basis:
			Year Ended December 31, 2014
			Derivative			Derivative			Total Fair Value
			liabilities -			liabilities -			Measurements
			Common Stock			Warrants			Using Level 3
									Inputs
	Beginning balance		$	558,799		$	64,788		$	623,587
	Issuance of warrants			-			2,550			2,550
	Anti-dilution shares to be issued			-1,771,362			-			-1,771,362
	Unrealized (gain) loss on derivative liabilities			1,301,434			-11,449			1,289,985
	Recognition of derivative liabilities			-			9,298			9,298
	Ending balance		$	88,871		$	65,187		$	154,058
			Year Ended December 31, 2013
			Derivative			Derivative			Total Fair Value
			liabilities -			liabilities -			Measurements
			Common Stock			Warrants			Using Level 3
									Inputs
	Beginning balance		$	-		$	-		$	-
	Issuance of warrants			-			45,685			45,685
	Unrealized (gain) loss on derivative liabilities			-257,846			-122,140			-379,986
	Recognition of derivative liabilities			816,645			141,243			957,888
	Ending balance		$	558,799		$	64,788		$	623,587

Longterm_Debt_Tables

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	Total debts outstanding are as follows:
				December 31, 2014		December 31, 2013
	1)	Note Payable to the WVDO		$	99,365	$	123,744
	2)	Note Payable to the WVEDA			141,369		147,306
	3)	Note Payable to the WVIJDC			139,128		145,078
	4)	Note Payable to the WVEDA			617,767		639,085
	5)	Note Payable to the WVIJDC			630,738		651,913
	6)	Note Payable to the WVJITB			290,000		290,000
	7)	Note Payable to the WVJITB			300,000		300,000
	8)	Note Payable to the WVHTCF			69,888		95,178
	9)	Note Payable to the WVEDA			166,258		170,932
	10)	Capital leases			820,524		71,077
		Total			3,275,037		2,634,313
		Less: current portion			-1,457,800		-1,054,053
		Long-term portion		$	1,817,237	$	1,580,260
Schedule of Maturities of Long-term Debt [Table Text Block]	Future required minimum principal repayments over the next five years are as follows:
	Year ending December 31:	Future required minimum principal repayments
	2014 (payments in arrears)	$	297,244
	2015		1,160,556
	2016		562,860
	2017		441,038
	2018		292,163
	2019& Thereafter		521,176
	Total	$	3,275,037

Common_Stock_Tables

Common Stock (Tables) (Common Stock [Member])	12 Months Ended
	Dec. 31, 2014
Common Stock [Member]
Schedule of Stock by Class [Table Text Block]	Common Stock issues during 2013 are as follows:
		# Shares		Par		Price		Gross		Value of		Par		Additional
		Issued		Value		Per		Proceeds		Services		Value		Paid in
						Share				Obtained				Capital (1)
	December 31, 2012 Balance		31,879,247	$	0.0001		Various	$	37,467,400	$	529,138	$	3,188	$	37,993,350
	Issuance of stock (2)		21,164,846		0.0001		0.5		10,582,423		-		2,116		10,580,307
	Issuance of stock (3)		575,000		0.0001		0.5		-		287,500		57		287,443
	Issuance of stock (3)		6,247		0.0001		2		-		12,494		1		12,493
	Issuance of stock (4)		527,500		0.0001		Various		-		-		53		-53
	Issuance of stock (5)		11,289,895		0.0001		0.5		5,644,948		-		1,130		5,643,818
	Total December 31, 2013		65,442,735					$	53,694,771	$	829,132	$	6,545	$	54,517,358
	(1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
	(2) Of the shares issued, 10,897,946 shares contained an anti-dilution provision expiring five years from date of issuance, 10,218,900 shares contained an anti-dilution provision that expired on 12/31/2013, and 48,000 shares did not contain an anti-dilution provision.
	(3) Shares issued for services performed.
	(4) Shares issued under anti-dilution provision.
	(5) Shares issued upon the conversion of convertible debentures. Of the total shares issued, 4,626,696 shares contained an anti-dilution provision expiring five years from date of issuance while 6,663,199 shares did not contain an anti-dilution provision.
	Common Stock issues during 2014 are as follows:
	Common Stock	# Shares		Par		Price		Gross		Value of		Par		Additional
		Issued		Value		Per		Proceeds		Services		Value		Paid in
						Share				Obtained				Capital (1)
	December 31, 2013 Balance		65,442,735		0.0001		Various	$	53,694,771	$	829,132	$	6,545	$	54,517,358
	Issuance of stock (2)		1,112,348		0.0001		Various		-		985,541		111		985,430
	Stock options exercised (3)		25,000		0.0001	$	0.55		13,750		-		2		13,748
	Stock warrants exercised (4)		8,517		0.0001	$	1.77		-		-		1		-1
	Total December 31, 2014		65,588,600					$	53,708,521	$	1,814,673	$	6,659	$	55,516,535
	(1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
	(2) Shares issued for services performed and does not contain an anti-dilution provision
	(3) Shares issued for exercised stock options and does not contain an anti-dilution provision
	(4) Shares issued under cashless stock warrant exercise and does not contain an anti-dilution provision

Preferred_Stock_Tables

Preferred Stock (Tables) (Preferred Stock [Member])	12 Months Ended
	Dec. 31, 2014
Preferred Stock [Member]
Schedule of Stock by Class [Table Text Block]	Preferred Stock	# Shares		Par		Price		Gross		Par		Additional
		Issued		Value		Per		Proceeds		Value		Paid in
						Share						Capital (1)
	December 31, 2013 Balance		-		-		-	$	-	$	-	$	-
	Issuance of stock (2)		2,264,238		0.0001	$	2		4,528,476		227		4,528,249
	Conversion of convertible debt (2)		1,073,487		0.0001	$	2		2,146,976		107		2,146,869
	Total December 31, 2014		3,337,725					$	6,675,452	$	334	$	6,675,118
	(1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
	(2) Shares issued contain an anti-dilution provision expiring upon the conversion to common stock.

Stock_Options_and_Stockbased_C1

Stock Options and Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of stock option activity is as follows:
			Shares			Weighted Average			Weighted Average Remaining
						Exercise Price			Contractual Life (in years)
	Outstanding at December 31, 2012			3,864,750		$	1.42			4
	Granted			1,768,000		$	0.55
	Exercised			-			-
	Cancelled or expired			-550,000		$	1.47
	Outstanding at December 31, 2013			5,082,750		$	1.11			7.02
	Granted			2,404,500		$	0.55
	Exercised			-25,000		$	0.55
	Cancelled or expired			-442,500		$	1.11
	Outstanding at December 31, 2014			7,019,750		$	0.92			6.69
	Exercisable at December 31, 2013			4,005,583		$	1.2			6.52
	Exercisable at December 31, 2014			4,596,467		$	1.11			5.95
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information about stock options at December 31, 2014:
				Options Outstanding								Options Exercisable
	Exercise Price			Outstanding			Weighted Average			Weighted		Exercisable		Weighted
							Remaining			Average				Average
							contractual life (in			Exercise				Exercise Price
							years)			Price
	$	0.5			159,000								133,625
	$	0.55			3,890,000								1,525,217
	$	0.8			320,000								320,000
	$	1.25			310,000								310,000
	$	1.5			2,126,000								2,092,875
	$	2			214,750								214,750
		$0.50 - $2.00			7,019,750			6.69		$	0.92		4,596,467	$	1.11
Schedule of Nonvested Share Activity [Table Text Block]	The following table summarizes the activity of the Company’s stock options that have not vested for the year ended December 31, 2014:
			Shares			Weighted Average
						Grant-date Fair Value
	Nonvested at December 31, 2012			872,333		$	0.441
	Granted			807,292		$	0.219
	Forfeited			-550,000		$	0.675
	Vested			-52,458		$	0.894
	Nonvested at December 31, 2013			1,077,167		$	0.467
	Granted			1,986,145		$	0.207
	Forfeited			-259,062		$	0.513
	Vested			-380,967		$	0.734
	Nonvested at December 31, 2014			2,423,283		$	0.258
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense is as follows:
			Year ended
			December 31, 2014			December 31, 2013
	Selling, general, and administrative expense		$	251,101		$	783,171
	Research and development expense			37,894			89,796
	Total stock-based compensation expense		$	288,995		$	872,967
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the option grants was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions:
		Year ended
			December 31, 2014			December 31, 2013
	Risk-free interest rate			1.91	%		1.56	%
	Volatility factor			70.03	%		73.56	%
	Weighted average expected life (in years)			7			7
	Dividend rate			0	%		0	%

Stock_Warrants_Tables

Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Stock Warrants [Abstract]
Schedule Of Warrant Activity [Table Text Block]			Shares			Weighted Average			Weighted Average Remaining
						Exercise			Contractual Life
						Price			(in years)
	Outstanding at December 31, 2013			52,705,614		$	1.3			2.58
	Granted			18,673,721		$	0.5			3.25
	Exercised			-22,500			-
	Cancelled or expired			-18,244,642		$	0.72
	Outstanding at December 31, 2014			53,112,193		$	0.98			3.27
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes information about stock warrants at December 31, 2014:
	Warrants Outstanding
	Exercise Price			Outstanding			Weighted Average Remaining			Weighted Average
							Contractual Life (in years)			Exercise Price
	$	0.375			13,350,898
	$	0.75			11,065,144
	$	0.8			1,415,000
	$	1.1			18,886,850
	$	1.12			263,750
	$	2			6,735,842
	$	2.2			98,320
	$	2.25			1,296,389
	$	0.375 - $2.25			53,112,193			3.27		$	0.98

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The valuation allowance is based on management’s current estimates of taxable income for the jurisdictions in which we operate and the period over which the deferred tax assets will be recoverable.
		December 31, 2014		December 31, 2013
	Current deferred income tax asset:
	Tax net operating loss carry forward	$	23,305,265	$	19,522,559
	Tax-deferred stock option expense		1,047,309		935,666
	Research and development expense		-		-
	Total current deferred income tax asset		24,352,574		20,458,225
	Valuation Allowance		-24,352,574		-20,458,225
	Net deferred income tax asset	$	-	$	-

Lease_Commitments_Tables

Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum rental payments are as follows for the year ending December 31, 2014:
	Year ending	Future minimum rental payments
	2014 (payment in arrears)	$	32,386
	2015	$	172,428
	2016	$	172,428
	2017	$	46,707
	2018	$	4,800
	2019 & Thereafter	$	4,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
French government R&D credit	$0	$400,379
Other receivables	119,230	34,899
Other receivables - current	119,230	435,278
Deposits	136,693	23,249
Other noncurrent assets	$136,693	$23,249

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory:
Finished goods	$18,739	$360,607
Work in progress	142,562	104,727
Total Inventory	$161,301	$465,334

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2)	12 Months Ended
	Dec. 31, 2014
Leaseholds and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Depreciation Methods	Life of lease
Computer [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Minimum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 3) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Lab equipment	$7,313,979	$6,620,662
Computer equipment	540,814	563,976
Office equipment	229,785	248,490
Leasehold improvements	434,304	477,682
Property, Plant and Equipment, Gross	8,518,882	7,910,810
Accumulated depreciation	-5,558,792	-5,024,634
Property and equipment, net	$2,960,090	$2,886,176

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Gross Revenue	$1,768,312	$1,223,492
Molecular Information Services [Member]
Segment Reporting Information [Line Items]
Gross Revenue	504,750	199,220
LAESI Instrument Platform [Member]
Segment Reporting Information [Line Items]
Gross Revenue	743,250	651,584
Research Products [Member]
Segment Reporting Information [Line Items]
Gross Revenue	400,141	372,688
Grants and Other Collaborations [Member]
Segment Reporting Information [Line Items]
Gross Revenue	$120,171	$0

Summary_of_Significant_Account8

Summary of Significant Accounting Policies (Details 5) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Payables And Accruals [Line Items]
Accrued expenses	$31,104	$653,047
Accrued interest	201,844	39,911
Accrued warranties	50,000	81,250
Accrued payroll and benefits	219,973	286,979
Unearned revenue	15,900	7,980
Other payables and accrued expenses	$518,821	$1,069,167

Summary_of_Significant_Account9

Summary of Significant Accounting Policies (Details 6) (Derivative Financial Instruments, Liabilities [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Risk Free Rate	1.38%
Fair Value Assumptions, Volatility	77.86%
Probability of a Capital Raise	100.00%	100.00%
Maximum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Expected Life (Years)	5 years	5 years
Fair Value Assumptions, Risk Free Rate		1.75%
Fair Value Assumptions, Volatility		88.30%
Minimum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Expected Life (Years)	1 year	1 year
Fair Value Assumptions, Risk Free Rate		0.13%
Fair Value Assumptions, Volatility		83.30%

Recovered_Sheet1

Summary of Significant Accounting Policies (Details 7) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	$154,058	$623,587
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	154,058	623,587	0
Derivative liabilities - common stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	88,871	558,799	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	88,871	558,799
Derivative liabilities - warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	65,187	64,788	0
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	$65,187	$64,788

Recovered_Sheet2

Summary of Significant Accounting Policies (Details 8) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	$623,587
Issuance of warrants	1,035,462	345,678
Ending balance	154,058	623,587
Derivative liabilities - warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	64,788	0
Issuance of warrants	2,550	45,685
Anti-dilution shares to be issued	0
Unrealized (gain) loss on derivative liabilities	-11,449	-122,140
Recognition of derivative liabilities	9,298	141,243
Ending balance	65,187	64,788
Derivative liabilities - common stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	558,799	0
Issuance of warrants	0	0
Anti-dilution shares to be issued	-1,771,362
Unrealized (gain) loss on derivative liabilities	1,301,434	-257,846
Recognition of derivative liabilities	0	816,645
Ending balance	88,871	558,799
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	623,587	0
Issuance of warrants	2,550	45,685
Anti-dilution shares to be issued	-1,771,362
Unrealized (gain) loss on derivative liabilities	1,289,985	-379,986
Recognition of derivative liabilities	9,298	957,888
Ending balance	154,058	623,587
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Ending balance	65,187	64,788
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - common stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Ending balance	$88,871	$558,799

Recovered_Sheet3

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Accounts Receivable, Net	$3,000	$4,000
Accrued Warranty Expense	50,000	81,250
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned	379,737	398,285
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	84,834,000	56,711,000
Depreciation, Depletion and Amortization, Total	825,780	844,888
Common stock Shares Future issuance	10,122,067
Common Stock Shares Issuable	$1,771,362	$0
Sales Revenue, Net [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Concentration Risk, Percentage	42.00%

Subsidiary_Sale_Details_Textua

Subsidiary Sale (Details Textual) (USD $)	0 Months Ended	6 Months Ended	12 Months Ended		1 Months Ended
	Dec. 12, 2014	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 27, 2014
Subsidiary, Sale of Stock [Line Items]
Preferred Stock Conversion Percentage		33.00%
Business Combination, Contingent Consideration Arrangements, Description		(a) a one-time milestone payment of $2,000,000 due within (10) days of receipt of the first approval by the FDA of a New Drug Application or Biologics License Application for a Business Product; (b) royalty payments equal to 2.5% of net sales of Business Product up to $100,000,000 and 1.5% of net sales of Business Product in excess of $100,000,000 and (c) ten percent (10%) of the Transaction Value received in connection with a sale or transfer of the pharmaceutical development business of Proteabio Europe
Gross proceeds raised and retained by the Buyer			$2,000,000
Equity Method Investment, Net Sales Proceeds	2,000,000
Equity Method Investment, Ownership Percentage	33.00%
Equity Method Investments			0
Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee			1,245,712	0
Proceeds from Divestiture of Businesses and Interests in Affiliates			586,638	0
Proceeds from Divestiture of Businesses, Net of Cash Divested			500,000
Debt Instrument, Increase (Decrease), Other, Net			100,000
Legal Fees			13,362
Proceeds from Divestiture of Interest in Consolidated Subsidiaries			2,000,000
Option Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested					300,000
Forgiveness [Member]
Subsidiary, Sale of Stock [Line Items]
Business Combination, Contingent Consideration, Liability, Noncurrent		100,000
Cash [Member]
Subsidiary, Sale of Stock [Line Items]
Business Combination, Contingent Consideration, Liability, Noncurrent		200,000
Purchase Price [Member]
Subsidiary, Sale of Stock [Line Items]
Business Combination, Contingent Consideration, Liability, Noncurrent		300,000
AzurRx Bio Pharma [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of Stock, Percentage of Ownership before Transaction		100.00%
Funding Operations			$761,258

Bank_Line_of_Credit_Details_Te

Bank Line of Credit (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity (in dollars)	$3,000,000
Line of Credit Facility, Interest Rate Description	The interest rate is variable and is .75% plus prime with a minimum rate of 5.87%
Line of Credit Facility, Amount Outstanding (in dollars)	$3,000,000	$2,725,000
Line of Credit Facility, Interest Rate at Period End	5.87%	5.87%

Loans_Payable_to_Stockholders_

Loans Payable to Stockholders (Details Textual) (USD $)	1 Months Ended		12 Months Ended		1 Months Ended
	Nov. 25, 2014	Oct. 31, 2014	Dec. 31, 2014		Aug. 06, 2013	Jun. 03, 2014	Sep. 25, 2014	Apr. 02, 2014	Sep. 30, 2014
Loans Payable to Stockholders [Line Items]
Warrants Issued to Purchase of Common Stock, Shares	4,293,948
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.375
Convertible Debt						$2,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			200,000
Preferred Stock [Member]
Loans Payable to Stockholders [Line Items]
Debt Conversion, Converted Instrument, Shares Issued		1,073,487	1,073,487	[1]
Convertible One-year Promissory Note [Member]
Loans Payable to Stockholders [Line Items]
Debt Instrument, Interest Rate, Effective Percentage			10.00%
Outstanding Principal And Accrued Unpaid Interest			100,000
Convertible Debt							3,000,000
Maximum [Member] | Convertible One-year Promissory Note [Member]
Loans Payable to Stockholders [Line Items]
Convertible Debt								300,000
Minimum [Member]
Loans Payable to Stockholders [Line Items]
Subsequent Financing proceeds			2,000,000
Summit Resources Inc [Member]
Loans Payable to Stockholders [Line Items]
Warrants Issued to Purchase of Common Stock, Shares					1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$1.10
Debt Instrument, Face Amount					600,000
Debt Instrument, Interest Rate, Effective Percentage			10.00%		10.00%
Repayments of Debt			423,915
Accretion Expense			94,757
Loans Payable			136,725
Pledged Assets, Not Separately Reported, Finance Receivables			130,000
Warrants and Rights Outstanding					134,117
Directors and Stock holders [Member]
Loans Payable to Stockholders [Line Items]
Due to Related Parties, Current									2,076,000
Due to Affiliate			540,000
Repayments of Related Party Debt			370,000
Summit Agreement [Member]
Loans Payable to Stockholders [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.8
Debt Instrument, Face Amount			1,415,000
Repayments of Debt			250,000
Accretion Expense			10,950
Loans Payable			1,074,773
Due to Related Parties, Current			1,415,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,415,000
Warrants and Rights Outstanding						101,177
Summit Agreement [Member] | Maximum [Member]
Loans Payable to Stockholders [Line Items]
Long-term Debt, Gross						1,500,000
Proceeds from Sale of Other Property, Plant, and Equipment					150,000
Summit Agreement [Member] | Minimum [Member]
Loans Payable to Stockholders [Line Items]
Long-term Debt, Gross						$900,000
[1]	Shares issued contain an anti-dilution provision expiring upon the conversion to common stock.

Obligation_Related_to_the_Lett1

Obligation Related to the Letter of Credit (Details Textual) (USD $)	0 Months Ended	12 Months Ended		0 Months Ended	1 Months Ended
	Mar. 06, 2013	Dec. 31, 2014	Dec. 31, 2013	Apr. 04, 2014	Jan. 21, 2014	Aug. 06, 2013	Mar. 31, 2013
Obligation Related to Letter of Credit [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		200,000
Director [Member] | Reimbursement Agreement [Member]
Obligation Related to Letter of Credit [Line Items]
Warrants and Rights Outstanding	$138,763
Discount to Reimbursement Agreement Balance	600,000
Accretion Expense		55,204	83,559
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,100,000
Director [Member] | Reimbursement Agreement [Member] | Payment Guarantee [Member]
Obligation Related to Letter of Credit [Line Items]
Accounts Payable, Other, Current		600,000
Summit Resources Inc [Member]
Obligation Related to Letter of Credit [Line Items]
Warrants and Rights Outstanding						134,117
Accretion Expense		94,757
Letter of Credit [Member] | Director [Member] | Reimbursement Agreement [Member]
Obligation Related to Letter of Credit [Line Items]
Due to Related Parties, Current			238,695
Repayments of Short-term Debt				90,835	147,860
Letter of Credit [Member] | Mpr Associates [Member] | Reimbursement Agreement [Member]
Obligation Related to Letter of Credit [Line Items]
Accounts Payable, Other, Current							$600,000

Longterm_Debt_Details

Long-term Debt (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	$3,275,037	$2,634,313
Less: current portion	-1,457,800	-1,054,053
Long-term portion	1,817,237	1,580,260
Note Payable To West Virginia Development Office [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	99,365	123,744
Note Payable To West Virginia Economic Development Authority, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	141,369	147,306
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	139,128	145,078
Note Payable To West Virginia Economic Development Authority, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	617,767	639,085
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	630,738	651,913
Note Payable To West Virginia Jobs Investment Trust Board, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	290,000	290,000
Note Payable To West Virginia Jobs Investment Trust Board, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	300,000	300,000
Note Payable To West Virginia High Technology Consortium Foundation [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	69,888	95,178
Note Payable to West Virginia Economic Development Authority, Series 3 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	166,258	170,932
Capital leases [Member]
Debt Instrument [Line Items]
Capital Lease Obligations	$820,524	$71,077

Longterm_Debt_Details_1

Long-term Debt (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Schedule of Capitalization, Long-term Debt [Line Items]
2014 (payments in arrears)	$297,244
2015	1,160,556
2016	562,860
2017	441,038
2018	292,163
2019& Thereafter	521,176
Total	$3,275,037	$2,634,313

Longterm_Debt_Details_Textual

Long-term Debt (Details Textual) (USD $)	1 Months Ended									12 Months Ended
	Mar. 31, 2007	Aug. 31, 2009	Oct. 31, 2010	Dec. 31, 2010	Mar. 31, 2012	Dec. 13, 2013	Apr. 30, 2012	31-May-12	Jun. 30, 2012	Dec. 31, 2014
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										200,000
Notes Payable to West Virginia Development Office [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument	8 years
Long-term Debt, Gross (in dollars)	$685,000
Debt Instrument, Interest Rate, Stated Percentage	3.00%
Number of Debt Instrument Periodic Payments	96 months
Debt Instrument, Periodic Payment	8,035
Debt Instrument, Maturity Date	30-Apr-15
Debt Instrument, Collateral	The note is secured by equipment
Pledged Assets, Not Separately Reported, Other	1,057,167
Notes Payable to West Virginia Economic Development Authority, Series 1 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument		10 years
Long-term Debt, Gross (in dollars)		242,631
Debt Instrument, Interest Rate, Stated Percentage		4.00%
Number of Debt Instrument Periodic Payments		120 months
Debt Instrument, Periodic Payment		2,457
Debt Instrument, Maturity Date		31-Aug-19
Debt Instrument, Collateral		The note is secured by 50% of equipment
Pledged Assets, Not Separately Reported, Other		569,812
Note Payable to West Virginia Infrastructure and Jobs Development Council, Series 1 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument		10 years
Long-term Debt, Gross (in dollars)		242,630
Debt Instrument, Interest Rate, Stated Percentage		3.25%
Number of Debt Instrument Periodic Payments		120 months
Debt Instrument, Periodic Payment		2,371
Debt Instrument, Maturity Date		31-Aug-19
Debt Instrument, Collateral		The note is secured by 50% of equipment
Pledged Assets, Not Separately Reported, Other		569,812
Note Payable to West Virginia Economic Development Authority, Series 2 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument			10 years
Long-term Debt, Gross (in dollars)			900,000
Debt Instrument, Interest Rate, Stated Percentage			3.26%
Number of Debt Instrument Periodic Payments			120 months
Debt Instrument, Periodic Payment			8,802
Debt Instrument, Maturity Date			31-Oct-20
Debt Instrument, Collateral			The note is secured by equipment
Pledged Assets, Not Separately Reported, Other			997,248
Note Payable to West Virginia Infrastructure and Jobs Development Council, Series 2 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument				10 years
Long-term Debt, Gross (in dollars)				900,000
Debt Instrument, Interest Rate, Stated Percentage				3.25%
Number of Debt Instrument Periodic Payments				120 months
Debt Instrument, Periodic Payment				8,781
Debt Instrument, Maturity Date				31-Dec-20
Debt Instrument, Collateral				The note is secured by equipment
Pledged Assets, Not Separately Reported, Other				1,098,249
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument					18 months
Long-term Debt, Gross (in dollars)					290,000
Debt Instrument, Interest Rate, Stated Percentage					6.00%
Debt Instrument, Maturity Date					30-Sep-13
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					72,500
Debt Instrument, Convertible, Conversion Price					$2
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member] | Due on March 15, 2014 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment						100,000
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member] | Due on June 15, 2014 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment						190,000
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 2 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument							3 months
Long-term Debt, Gross (in dollars)							400,000
Debt Instrument, Interest Rate, Stated Percentage							10.00%
Debt Instrument, Periodic Payment							100,000
Debt Instrument, Periodic Payment, Principal							100,000
Debt Instrument, Maturity Date							30-Jun-12
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							88,889
Debt Instrument, Convertible, Conversion Price							$0.50
Debt Instrument, Face Amount							300,000
Convertible Promissory Note Payable to West Virginia High Technology Consortium Foundation [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument								30 months
Long-term Debt, Gross (in dollars)								200,000
Debt Instrument, Interest Rate, Stated Percentage								8.00%
Number of Debt Instrument Periodic Payments								25 months
Debt Instrument, Periodic Payment								9,001
Debt Instrument, Maturity Date								30-Nov-14
Debt Instrument, Collateral								The note is secured by 50% of equipment
Debt Instrument, Convertible, Conversion Price								$0.50
Pledged Assets, Not Separately Reported, Other								447,320
Note Payable to West Virginia Economic Development Authority, Series 3 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument									10 years
Long-term Debt, Gross (in dollars)									200,000
Debt Instrument, Interest Rate, Stated Percentage									2.00%
Number of Debt Instrument Periodic Payments									120 months
Debt Instrument, Periodic Payment									1,840
Debt Instrument, Maturity Date									30-Jun-22
Debt Instrument, Collateral									The note is secured by 50% of equipment
Pledged Assets, Not Separately Reported, Other									$447,320
Capital Leases [Member]
Debt Instrument [Line Items]
Lease Expiration Date										May 2015 through October 2019
Capital Lease Obligation Collateral										secured by equipment with an aggregate cost of $1,095,751
Capital Leases [Member] | Maximum [Member]
Debt Instrument [Line Items]
Duration of Lease										60 months
Imputed Interest Rate										6.11%
Capital Leases [Member] | Minimum [Member]
Debt Instrument [Line Items]
Duration of Lease										30 months
Imputed Interest Rate										5.96%

Common_Stock_Details

Common Stock (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Class of Stock [Line Items]
Balance at December 31, 2013, Par Value (in dollars per share)	$0.00		$0.00
Issuance of stock, Gross Proceeds (in dollars)	$13,750		$9,352,837
Balance	6,545
Issuance of stock for services	880,373		299,994
Stock Options exercised, Par Value (in dollars)	19,265
Stock warrants exercised	0
Balance	6,659		6,545
Balance at December 31, 2013, Additional Paid in Capital (in dollars)	55,351,613
Balance at December 31,2013, Additional Paid in Capital (in dollars)	64,305,743		55,351,613
Common Stock [Member]
Class of Stock [Line Items]
Balance (in shares)	65,442,735		31,879,247
Issuance of stock, Shares issued (in shares)	1,112,348		581,247
Stock Options exercised, Shares issued (in shares)	25,000	[1]
Stock warrants exercised, Shares issued (in shares)	8,517	[2]
Balance (in shares)	66,588,600		65,442,735
Balance at December 31, 2013, Par Value (in dollars per share)			$0.00		$0.00
Stock Options exercised, Par Value (in dollars per share)	$0.00	[1]
Stock warrants exercised, Par Value (in dollars per share)	$0.00	[2]
Balance at December 31, 2013, Price Per Share (in dollars per share)	Various		Various
Stock Options exercised, Price Per Share (in dollars per share)	$0.55	[1]
Stock warrants exercised, Price Per Share (in dollars per share)	$1.77	[2]
Balance at December 31, 2013, Gross Proceeds (in dollars)	53,694,771		37,467,400
Stock Options exercised, Gross Proceeds (in dollars)	13,750	[1]
Stock warrants exercised, Gross Proceeds (in dollars)	0	[2]
Balance at December 31.2013, Gross Proceeds (in dollars)	53,708,521		53,694,771
Balance at December 31, 2013, Value of Services Obtained (in dollars)	829,132		529,138
Stock Options exercised, Value of Services Obtained (in dollars)	0	[1]
Stock warrants exercised, Value of Services Obtained (in dollars)	0	[2]
Balance at December 31,2013, Value of Services Obtained (in dollars)	1,814,673		829,132
Balance	6,545		3,188
Issuance of stock for services	111		58
Stock Options exercised, Par Value (in dollars)	2	[1]
Stock warrants exercised	1	[2]
Balance	6,659		6,545
Balance at December 31, 2013, Additional Paid in Capital (in dollars)	54,517,358	[3]	37,993,350	[3]
Stock Options exercised, Additional Paid in Capital (in dollars)	13,748	[1],[3]
Stock warrants exercised, Additional Paid in Capital (in dollars)	-1	[2],[3]
Balance at December 31,2013, Additional Paid in Capital (in dollars)	55,516,535	[3]	54,517,358	[3]
Issuance of stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	1,112,348	[4]	21,164,846	[5]
Issuance of stock, Par Value (in dollars per share)	$0.00	[4]	$0.00	[5]
Issuance of stock, Price Per Share (in dollars per share)	Various	[4]
Stock Options exercised, Price Per Share (in dollars per share)			$0.50	[5]
Issuance of stock, Gross Proceeds (in dollars)	0	[4]	10,582,423	[5]
Issuance of stock, Value of Services Obtained (in dollars)	985,541	[4]	0	[5]
Issuance of stock for services	111	[4]	2,116	[5]
Issuance of stock, Additional Paid in Capital (in dollars)	985,430	[3],[4]	10,580,307	[3],[5]
Issuance of stock 1 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)			575,000	[6]
Issuance of stock, Par Value (in dollars per share)			$0.00	[6]
Stock Options exercised, Price Per Share (in dollars per share)			$0.50	[6]
Issuance of stock, Gross Proceeds (in dollars)			0	[6]
Issuance of stock, Value of Services Obtained (in dollars)			287,500	[6]
Issuance of stock for services			57	[6]
Issuance of stock, Additional Paid in Capital (in dollars)			287,443	[3],[6]
Issuance of stock 2 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)			6,247	[6]
Issuance of stock, Par Value (in dollars per share)			$0.00	[6]
Stock Options exercised, Price Per Share (in dollars per share)			$2	[6]
Issuance of stock, Gross Proceeds (in dollars)			0	[6]
Issuance of stock, Value of Services Obtained (in dollars)			12,494	[6]
Issuance of stock for services			1	[6]
Issuance of stock, Additional Paid in Capital (in dollars)			12,493	[3],[6]
Issuance of stock 3 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)			527,500	[7]
Issuance of stock, Par Value (in dollars per share)			$0.00	[7]
Issuance of stock, Price Per Share (in dollars per share)			Various	[7]
Issuance of stock, Gross Proceeds (in dollars)			0	[7]
Issuance of stock, Value of Services Obtained (in dollars)			0	[7]
Issuance of stock for services			53	[7]
Issuance of stock, Additional Paid in Capital (in dollars)			-53	[3],[7]
Issuance of stock 4 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)			11,289,895	[8]
Issuance of stock, Par Value (in dollars per share)			$0.00	[8]
Stock Options exercised, Price Per Share (in dollars per share)			$0.50	[8]
Issuance of stock, Gross Proceeds (in dollars)			5,644,948	[8]
Issuance of stock, Value of Services Obtained (in dollars)			0	[8]
Issuance of stock for services			1,130	[8]
Issuance of stock, Additional Paid in Capital (in dollars)			$5,643,818	[3],[8]
[1]	Shares issued for exercised stock options and does not contain an anti-dilution provision
[2]	Shares issued under cashless stock warrant exercise and does not contain an anti-dilution provision
[3]	Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
[4]	Shares issued for services performed and does not contain an anti-dilution provision
[5]	Of the shares issued, 10,897,946 shares contained an anti-dilution provision expiring five years from date of issuance, 10,218,900 shares contained an anti-dilution provision that expired on 12/31/2013, and 48,000 shares did not contain an anti-dilution provision.
[6]	Shares issued for services performed.
[7]	Shares issued under anti-dilution provision.
[8]	Shares issued upon the conversion of convertible debentures. Of the total shares issued, 4,626,696 shares contained an anti-dilution provision expiring five years from date of issuance while 6,663,199 shares did not contain an anti-dilution provision.

Common_Stock_Details_Textual

Common Stock (Details Textual)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Shares Authorized Total	210,000,000
Common Stock, Shares Authorized	200,000,000	200,000,000
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common Stock, Voting Rights	Common Stock – par value of $.0001 per share with one vote in respect of each share held. Holders of Common Stock do not have cumulative voting rights
Anti Dilution Provision [Member]
Class of Stock [Line Items]
Anti Dilution Provision Expiration Period	5 years
Anti Dilution Provision One [Member]
Class of Stock [Line Items]
Anti Dilution Provision Expiration Period	5 years
Stock Issued During Period, Shares, Conversion of Convertible Securities	4,626,696
Stock Issued During Period Shares Without Anti Dilution Rights	10,897,946
Anti Dilution Provision Two [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares Anti Dilution Rights	10,218,900
Issuance Of Stock Five [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares Without Anti Dilution Rights	6,663,199
Issuance Of Stock One [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares Without Anti Dilution Rights	48,000

Preferred_Stock_Details

Preferred Stock (Details) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014		Dec. 31, 2013	Oct. 31, 2014
Class of Stock [Line Items]
Proceeds from sale of preferred stock, net	$3,713,872		$0
Preferred stock, par value (in dollars per share)	$0.00		$0.00
December 31, 2013 Balance par value	0
Debt converted to company stock	2,146,976		5,644,948
Total December 31, 2014 par value	334		0
Conversion of convertible debt , Additional Paid in Capital			763,659
Preferred Stock [Member]
Class of Stock [Line Items]
Balance (in shares)	0
Issuance of stock, Shares issued (in shares)	2,264,238	[1]
Conversion of convertible debt, Shares issued(in shares)	1,073,487	[1]		1,073,487
Balance (in shares)	3,337,725
Conversion of convertible debt, price per share (in dollars per share)	$2	[1]
Debt Instrument, Convertible, Conversion Price	$2	[1]
Gross proceeds from conversion of convertible debt December 31, 2013	6,675,452
Proceeds from sale of preferred stock, net	4,528,476	[1]
Conversion of convertible debt ,Gross proceeds	2,146,976	[1]
Preferred stock, par value (in dollars per share)	$0.00	[1]
Gross proceeds from conversion of convertable debt December 31, 2014	0
December 31, 2013 Balance par value	0
Issuance of stock, Value of Services Obtained	227	[1]
Debt converted to company stock	107	[1]
Total December 31, 2014 par value	334
Total December 31, 2014 Additional Paid in Capital	6,675,118	[2]
Issuance of stock, Additional Paid in Capital	4,528,249	[1],[2]
Conversion of convertible debt , Additional Paid in Capital	2,146,869	[1],[2]
Balance at December 31,2013, Additional Paid in Capital	$0	[2]
Preferred Stock [Member] | Convertible Debt [Member]
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$0.00	[1]
[1]	Shares issued contain an anti-dilution provision expiring upon the conversion to common stock.
[2]	Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.

Preferred_Stock_Details_Textua

Preferred Stock (Details Textual) (USD $)	12 Months Ended		2 Months Ended
	Dec. 31, 2014		Feb. 17, 2015
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion	27,125,016
Warrant Term	3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.38
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	200,000
Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	2,264,238	[1]
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	50,000
Share Price	$2
Preferred Stock, Dividend Rate, Percentage	6.00%
Convertible Preferred Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Preferred Stock, Conversion Basis			The Preferred Stock will automatically convert into shares of Common Stock determined by dividing the stated value by $0.25 per share on February 17, 2015.
[1]	Shares issued contain an anti-dilution provision expiring upon the conversion to common stock.

Stock_Options_and_Stockbased_C2

Stock Options and Stock-based Compensation (Details) (Employee Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding	5,082,750	3,864,750
Shares, Granted	2,404,500	1,768,000
Shares, Exercised	-25,000	0
Shares, Cancelled or expired	-442,500	-550,000
Shares, Outstanding	7,019,750	5,082,750	3,864,750
Shares Exercisable	4,596,467	4,005,583
Weighted Average Exercise Price, Outstanding	$1.11	$1.42
Weighted Average Exercise Price, Granted	$0.55	$0.55
Weighted Average Exercise Price, Exercised	$0.55	$0
Weighted Average Exercise Price, Cancelled or expired	$1.11	$1.47
Weighted Average Exercise Price, Outstanding	$0.92	$1.11	$1.42
Weighted Average Exercise Price, Exercisable	$1.11	$1.20
Weighted Average Remaining Contractual Life (in years), Outstanding	6 years 8 months 8 days	7 years 7 days	4 years
Weighted Average Remaining Contractual Life (in years), Exercisable	5 years 11 months 12 days	6 years 6 months 7 days

Stock_Options_and_Stockbased_C3

Stock Options and Stock-based Compensation (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Limit (in dollars per share)	$0.50
Options Outstanding, Exercise Price, Upper Limit (in dollars per share)	$2
Options Outstanding (in shares)	7,019,750
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	6 years 8 months 8 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$0.92
Options Exercisable (in shares)	4,596,467
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$1.11
Exercise Price 0.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share)	$0.50
Options Outstanding (in shares)	159,000
Options Exercisable (in shares)	133,625
Exercise Price 0.55 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share)	$0.55
Options Outstanding (in shares)	3,890,000
Options Exercisable (in shares)	1,525,217
Exercise Price 0.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share)	$0.80
Options Outstanding (in shares)	320,000
Options Exercisable (in shares)	320,000
Exercise Price 1.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share)	$1.25
Options Outstanding (in shares)	310,000
Options Exercisable (in shares)	310,000
Exercise Price 1.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share)	$1.50
Options Outstanding (in shares)	2,126,000
Options Exercisable (in shares)	2,092,875
Exercise Price 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share)	$2
Options Outstanding (in shares)	214,750
Options Exercisable (in shares)	214,750

Stock_Options_and_Stockbased_C4

Stock Options and Stock-based Compensation (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Nonvested, Beginning Balance	1,077,167	872,333
Shares, Granted	1,986,145	807,292
Shares, Forfeited	-259,062	-550,000
Shares, Vested	-380,967	-52,458
Shares, Nonvested at Ending Balance	2,423,283	1,077,167
Weighted Average Grant-date Fair Value, Nonvested, Beginning Balance	$0.47	$0.44
Weighted Average Grant-date Fair Value, Granted	$0.21	$0.22
Weighted Average Grant-date Fair Value, Forfeited	$0.51	$0.68
Weighted Average Grant-date Fair Value, Vested	$0.73	$0.89
Weighted Average Grant-date Fair Value, Nonvested, Ending Balance	$0.26	$0.47

Stock_Options_and_Stockbased_C5

Stock Options and Stock-based Compensation (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$283,481	$872,967
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	251,101	783,171
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$37,894	$89,796

Stock_Options_and_Stockbased_C6

Stock Options and Stock-based Compensation (Details 4)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.91%	1.56%
Volatility factor	70.03%	73.56%
Weighted average expected life (in years)	7 years	7 years
Dividend rate	0.00%	0.00%

Stock_Options_and_Stockbased_C7

Stock Options and Stock-based Compensation (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2002
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$0
Share-based Compensation Arrangement by Share-based Payment Award Estimated Fair Value of Stock Price (in dollars per share)	$0.39
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in dollars)	288,995	477,353
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$0.21	$0.22
Share-based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Fair Value	$478,912
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Expected Term	1 year 9 months 18 days
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Description	The Company completed an analysis and identified four similar companies considering their industry, stage of life cycle, size, and financial leverage.
Equity Incentive Plan 2002 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			4,150,000	450,000
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	5,000,000

Stock_Warrants_Details

Stock Warrants (Details) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Class of Warrant or Right [Line Items]
Shares, Outstanding at December 31, 2013	52,705,614
Shares, Granted	18,673,721
Shares, Exercised	-22,500
Shares, Cancelled or expired	-18,244,642
Shares, Outstanding at September 30, 2014	53,112,193	52,705,614
Weighted Average Exercise Price, Outstanding at December, 2013	$1.30
Weighted Average Exercise Price, Granted	$0.50
Weighted Average Exercise Price, Exercised	$0
Weighted Average Exercise Price, Cancelled or expired	$0.72
Weighted Average Exercise Price, Outstanding at September 30, 2014	$0.98	$1.30
Weighted Average Remaining Contractual Life (in years), Outstanding	3 years 3 months 7 days	2 years 6 months 29 days
Weighted Average Remaining Contractual Life (in years), Granted	3 years 3 months

Stock_Warrants_Details_1

Stock Warrants (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$0.38
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	53,112,193
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	3 years 3 months 7 days	2 years 6 months 29 days
Warrant Outstanding, Weighted Average Exercise Price (in dollars per share)	$0.98	$1.30
Warrant [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$2.25
Warrant [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$0.38
Warrant [Member] | Exercise Price 0.375
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$0.38
Warrants Outstanding (in shares)	13,350,898
Warrant [Member] | Exercise Price 0.75
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$0.75
Warrants Outstanding (in shares)	11,065,144
Warrant [Member] | Exercise Price 0.80
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$0.80
Warrants Outstanding (in shares)	1,415,000
Warrant [Member] | Exercise Price 1.10
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$1.10
Warrants Outstanding (in shares)	18,886,850
Warrant [Member] | Exercise Price 1.12
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$1.12
Warrants Outstanding (in shares)	263,750
Warrant [Member] | Exercise Price 2.00
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$2
Warrants Outstanding (in shares)	6,735,842
Warrant [Member] | Exercise Price 2.20
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$2.20
Warrants Outstanding (in shares)	98,320
Warrant [Member] | Exercise Price 2.25
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$2.25
Warrants Outstanding (in shares)	1,296,389

Stock_Warrants_Details_Textual

Stock Warrants (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Ability to Purchase Common Stock		7,592,400
Placement Agent Services	$49,921	$537,137
Granting and Accruing Warrants	3,720,323
Interest Expense, Other	$192,421
Class Of Warrant Or Right Term Of Warrants Or Rights Term		5 years
Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	53,112,193
Common Stock [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right Term of Warrants or Rights	$0.38
Common Stock [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right Term of Warrants or Rights	$2.25
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	53,112,193
Warrant [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right Term of Warrants or Rights		$0.50
Warrant [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right Term of Warrants or Rights		$1.10

Income_Taxes_Details

Income Taxes (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current deferred income tax asset:
Tax net operating loss carry forward	$23,305,265	$19,522,559
Tax-deferred stock option expense	1,047,309	935,666
Research and development expense	0	0
Total current deferred income tax asset	24,352,574	20,458,225
Valuation Allowance	-24,352,574	-20,458,225
Net deferred income tax asset	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Operating Loss Carryforwards, Expiration Dates	expire beginning 2021 for both federal and state purposes.
Income Tax Examination, Likelihood of Unfavorable Settlement	greater than 50% likelihood
Operating Loss Carryforwards	$59,800,000	$50,000,000
Deferred Tax Assets, Valuation Allowance	$24,352,574	$20,458,225

Lease_Commitments_Details

Lease Commitments (Details) (USD $)	Dec. 31, 2014
Lease Commitments [Line Items]
2014 (payment in arrears)	$32,386
2015	172,428
2016	172,428
2017	46,707
2018	4,800
2019 & Thereafter	$4,000

Lease_Commitments_Details_Text

Lease Commitments (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Lease Commitments [Line Items]
Description of Lessor Leasing Arrangements, Operating Leases	The Company leases its facilities under operating leases beginning a) February 2005 and extended through December 2012 with a month-to-month to lease subsequent to the lease term period and b) April 2012 through March 2017.
Operating Leases, Rent Expense (in dollars)	$371,198	$435,863
Maximum [Member]
Lease Commitments [Line Items]
Lessee Leasing Arrangements, Operating Leases, Term of Contract	5 years

Retirement_Plan_Details_Textua

Retirement Plan (Details Textual)	12 Months Ended
	Dec. 31, 2014
Retirement Plan [Line Items]
Description of Postemployment Benefits	The Company provides a 401(k) Profit Sharing Plan for elective deferrals whereby participants can defer up to 100% of their wages not to exceed a maximum dollar amount determined by the Federal Government each year.

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual)

12 Months Ended

12 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

USD ($)

USD ($)

Omics2image [Member]

Omics2image [Member]

Capital Addition Purchase Commitments [Member]

George Washington University (GWU) [Member]

George Washington University (GWU) [Member]

Dynamic Manufacturing LLC [Member]

Bridger Photonics [Member]

COAST Project [Member]

COAST Project [Member]

Navitas Lease Corp [Member]

USD ($)

EUR (€)

USD ($)

USD ($)

Royalty Agreements [Member]

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

Loss Contingencies [Line Items]

Malpractice Insurance, Maximum Coverage Per Incident (in dollars)

$5,000,000

Standard Product Warranty Description

1 year

Royalty Expenses (in dollars)

45,500

34,700

Accounts Payable and Accrued Liabilities, Current (in dollars)

124,000

59,000

Commitments Outstanding

373,300

21,900

77,000

60,000

68,000

License Costs

25,000

Minimum License Diligence Resources Year Two

12,500

Minimum License Diligence Resources After Year Two

20,000

License and Maintenance Revenue

30,000

Royalties Percentage on Net Sales of Licensed Products

7.00%

Royalties Percentage on Combination Products for Combined Cumulative Net Sales

5.00%

Sales Revenue, Services, Net

50,000,000

Reduce Royalties Percentage After Net Sales of Licensed Products

6.00%

Reduce Royalties Percentage on Combination Products for Combined Cumulative After Net Sales

4.00%

Minimum Royalties Year One

1,500

Minimum Royalties Year Two

2,500

Minimum Royalties Year Three

3,500

Minimum Royalties Year After Three Year

6,000

Accrued warranties

50,000

81,250

Commitment On Equipment Purchase

326,000

Long-term Purchase Commitment, Amount

104,524

26,266

Payment for Royalty

50,900

Accrued Liabilities, Current

31,104

653,047

29,300

Payments to Acquire Projects

$25,500

€ 20,000

Evaluation_of_Subsequent_Event1

Evaluation of Subsequent Events (Details Textual) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Feb. 28, 2015	Dec. 31, 2012
Subsequent Event [Line Items]
Proceeds from Related Party Debt	$3,595,000	$1,000,000
Proceeds from Issuance or Sale of Equity	2,000,000
Preferred Stock, Shares Issued	3,337,725	0
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Common Stock, Par or Stated Value Per Share	$0.00	$0.00
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.38
Common Stock, Shares, Issued	66,588,600	65,442,735
Common Stock [Member]
Subsequent Event [Line Items]
Common Stock, Par or Stated Value Per Share		$0.00		$0.00
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Related Party Debt	298,000
Warrants To Purchase Common Stock			200,000
Proceeds from Issuance or Sale of Equity			100,000
Preferred Stock, Shares Issued			50,000
Preferred Stock, Par or Stated Value Per Share			$2
Common Stock, Shares, Issued			200,000
Subsequent Event [Member] | Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred Stock, Conversion Basis			The Preferred Stock will automatically convert into shares of Common Stock determined by dividing the Stated Value by $0.25 per share on February 17, 2015.
Preferred Stock, Dividend Rate, Percentage	6.00%
Subsequent Event [Member] | Placement Agent [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued			60,000
Payments of Stock Issuance Costs			$10,000
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Common Stock, Par or Stated Value Per Share			$0.00
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.38
Warrants Expiration Period			3 years
Subsequent Event [Member] | Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred Stock, Shares Issued			50,000
Preferred Stock, Par or Stated Value Per Share			$0.00